Phytotherapy and Nutritional Supplements on Breast Cancer

BioMed Research International

Volumn 2017, Issue , 2017, Pages

  Lopes, C M ^a   Dourado, A ^b   Oliveira, R ^a  

^a UNIVERSIDADE FERNANDO PESSOA   (Portugal)

^b EMAC (School of Alternative and Complementary Medicines)   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ASCORBIC ACID; CALCIUM; CAROTENOID; MULTIVITAMIN; NUTRITION SUPPLEMENT; OMEGA 3 FATTY ACID; PLANT MEDICINAL PRODUCT; RETINOL; SELENIUM; VITAMIN B COMPLEX; VITAMIN D; PLANT EXTRACT; VITAMIN;

ACTAEA RACEMOSA; BREAST CANCER; CURCUMA LONGA; ECHINACEA; FLAX; GARLIC; GINSENG; HEALTH HAZARD; HUMAN; LAPACHO; MEDICINAL PLANT; METHODOLOGY; MISTLETOE; PHYTOTHERAPY; REVIEW; SALVIA; TEA; UNCARIA; ACTAEA; ADJUVANT CHEMOTHERAPY; BREAST TUMOR; DIETARY SUPPLEMENT; FEMALE; PANAX;

BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CIMICIFUGA; DIETARY SUPPLEMENTS; FEMALE; HUMANS; PANAX; PHYTOTHERAPY; PLANT EXTRACTS; TEA; VITAMINS;

EID: 85028328536     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2017/7207983     Document Type: Review

References (439)

1. P. M. Sowa, M. J. Downes, and L. G. Gordon, "RETRACTED ARTICLE: Cost-effectiveness of dual energy X-ray absorptiometry (DXA) plus anti-resorptive treatment in Australian women with breast cancer who receive aromatase inhibitors, " Journal of Bone and Mineral Metabolism, vol. 34, no. 2, p. 242, 2016.
2. A. Soliman, S. Samadi, M. Banerjee, and Z. Aziz, "Brief Continuing Medical Education (CME) module raises knowledge of developing country physicians, " The International Electronic Journal of Health Education, vol. 9, pp. 31-41, 2006.
3. R. E. Rossi, M. Pericleous, D. Mandair, T. Whyand, and M. E. Caplin, "The role of dietary factors in prevention and progression of breast cancer, " Anticancer Research, vol. 34, no. 12, pp. 6861-6875, 2014.
4. WHO, World Health Organization: Breast Cancer: Prevention and Control, 2017, http://www. who. int/cancer/detection/breastcancer/ en/index1. html.
5. N. K. Lina, "Knowledge about breast cancer and negative influences affecting breast cancer screening among women in Jordan, " IJHSS, vol. 2, pp. 1-11, 2012.
6. H. S. Boon, F. Olatunde, and S. M. Zick, "Trends in complementary/ alternative medicine use by breast cancer survivors: Comparing survey data from 1998 and 2005, " BMC Women's Health, vol. 7, article 4, 2007.
7. T. Nagykálnai, L. Landherr, and A. C. Nagy, "Vitamin D and breast cancer, " Orvosi Hetilap, vol. 155, no. 28, pp. 1091-1096, 2014.
8. C. Alliance, The Regulatory Status of Complementary and AlternativeMedicine forMedical Doctors in Europe, 2015, http:// www. camdoc. eu/Pdf/CAMDOCRegulatoryStatus8 10. pdf.
9. L. T. Nguyen, R. B. Davis, T. J. Kaptchuk, and R. S. Phillips, "Use of complementary and alternativemedicine and self-rated health status: results from a national survey, " Journal of General Internal Medicine, vol. 26, no. 4, pp. 399-404, 2011.
10. J. Saquib, L. Madlensky, S. Kealey et al., "Classification of CAM use and its correlates in patients with early-stage breast cancer, " Integrative CancerTherapies, vol. 10, no. 2, pp. 138-147, 2011.
11. J. A. Bennett, L. D. Cameron, L. C. Whitehead, and D. Porter, "Differences between older and younger cancer survivors in seeking cancer information and using complementary/ alternative medicine, " Journal of General InternalMedicine, vol. 24, no. 10, pp. 1089-1094, 2009.
12. A. Wanchai, J. M. Armer, and B. R. Stewart, "Complementary and alternative medicine use among women with breast cancer: A systematic review, " Clinical Journal of Oncology Nursing, vol. 14, no. 4, pp. E45-E55, 2010.
13. National Center for Complementary and Integrative Medicine (NCCIM), Complementary, Alternative, or Integrative Health: What's in a Name?, 2015, https://nccih. nih. gov/health/integrativehealth.
14. National Cancer Institute (NCI), Thinking about Complementary and Alternative Medicine: A Guide for People with Cancer, 2015, http://www. cancer. gov/publications/patient-education/ 367NCINewV2. pdf.
15. G. Dobos and I. Tao, "The model of Western integrative medicine: The role of Chinese medicine, " Chinese Journal of Integrative Medicine, vol. 17, no. 1, pp. 11-20, 2011.
16. G. J. Dobos, P. Voiss, I. Schwidde et al., "Integrative oncology for breast cancer patients: Introduction of an expert-based model, " BMC Cancer, vol. 12, article no. 539, 2012.
17. M. Horneber, G. Bueschel, G. Dennert, D. Less, E. Ritter, and M. Zwahlen, "How many cancer patients use complementary and alternative medicine: A systematic review and metaanalysis, " Integrative CancerTherapies, vol. 11, no. 3, pp. 187-203, 2012.
18. O. Micke, F. Bruns, M. Glatzel et al., "Predictive factors for the use of complementary and alternative medicine (CAM) in radiation oncology, " European Journal of Integrative Medicine, vol. 1, no. 1, pp. 19-25, 2009.
19. M. Vidal, C. Carvalho, and R. Bispo, "Use of complementary and alternative medicine in a sample of women with breast cancer, " SAGE Open, pp. 1-4, 2013.
20. T. Gansler, C. Kaw, C. Crammer, and T. Smith, "A populationbased study of prevalence of complementary methods use by cancer survivors: A report from the American cancer society's studies of cancer survivors, " Cancer, vol. 113, no. 5, pp. 1048-1057, 2008.
21. V. S. Eschiti, "Lesson from comparison of CAM use by women with female-specific cancers to others: It's time to focus on interaction risks with CAM therapies, " Integrative CancerTherapies, vol. 6, no. 4, pp. 313-344, 2007.
22. J. A. Astin, C. Reilly, C. Perkins, and W. L. Child, "Breast cancer patients' perspectives on and use of complementary and alternative medicine: A study by the Susan G. Komen Breast Cancer Foundation, " Journal of the Society for Integrative Oncology, vol. 4, no. 4, pp. 157-169, 2006.
23. N. Tung, "What is the optimal endocrine therapy for postmenopausal women with hormone receptor-positive early breast cancer?" Journal of Clinical Oncology, vol. 31, no. 11, pp. 1391-1397, 2013.
24. A. Molassiotis, P. Fernandez-Ortega, D. Pud et al., "Use of complementary and alternative medicine in cancer patients: A European survey, " Annals of Oncology, vol. 16, no. 4, pp. 655-663, 2005.
25. T. Kremser, A. Evans, A. Moore et al., "Use of complementary therapies by Australian women with breast cancer, " The Breast, vol. 17, no. 4, pp. 387-394, 2008.
26. J. Saquib, C. L. Rock, L. Natarajan et al., "Dietary intake, supplement use, and survival among women diagnosed with early-stage breast cancer, " Nutrition and Cancer, vol. 63, no. 3, pp. 327-333, 2011.
27. Z. Hu, X. Yang, P. C. L. Ho et al., "Herb-drug interactions: A literature review, " Drugs, vol. 65, no. 9, pp. 1239-1282, 2005.
28. G. A. Saxe, L. Madlensky, S. Kealey, D. P. H. Wu, K. L. Freeman, and J. P. Pierce, "Disclosure to physicians of CAMuse by breast cancer patients: Findings from the women's healthy eating and living study, " Integrative CancerTherapies, vol. 7, no. 3, pp. 122-129, 2008.
29. A. Cassidy, "Are herbal remedies and dietary supplements safe and effective for breast cancer patients?" Breast Cancer Research, vol. 5, no. 6, pp. 300-302, 2003.
30. H. Ma, C. L. Carpenter, J. Sullivan-Halley, and L. Bernstein, "The roles of herbal remedies in survival and quality of life among long-term breast cancer survivors-results of a prospective study, " BMC Cancer, vol. 11, article no. 222, 2011.
31. Z. O. Omogbadegun, "Medicinal plants-based foods for breast cancer treatment: An ethnobotanical survey and digitization, " International Journal of Medicinal Plants and Alternative Medicine, vol. 1, pp. 137-163, 2013.
32. M. J. Wargovich, C. Woods, D. M. Hollis, and M. E. Zander, "Herbals, cancer prevention and health, " Journal of Nutrition, vol. 131, no. 11, pp. 3034S-3036S, 2001.
33. J. S. McLay, D. Stewart, J. George, C. Rore, and S. D. Heys, "Complementary and alternative medicines use by Scottish womenwith breast cancer. What, why and the potential for drug interactions?" European Journal of Clinical Pharmacology, vol. 68, no. 5, pp. 811-819, 2012.
34. M. Bright-Gbebry, K. H. Makambi, J. P. Rohan et al., "Use of multivitamins, folic acid and herbal supplements among breast cancer survivors: The black women's health study, " BMC Complementary and Alternative Medicine, vol. 11, article no. 30, 2011.
35. W. J. Craig, "Health-promoting properties of common herbs, " Am J Clin Nutr, vol. 70, 3, pp. 491S-499S, 1999.
36. S. N. Driggins, E. L. Myles, and T. Gary, "The anti-prolific effect of Echinacea Pallida on BT-549 cancer cell line, " Proc Amer Assoc Cancer Res, vol. 45, 2004.
37. E. D. Huntimer, F. T. Halaweish, and C. C. L. Chase, "Proliferative activity of Echinacea angustifolia root extracts on cancer cells: Interference with doxorubicin cytotoxicity, " Chemistry and Biodiversity, vol. 3, no. 6, pp. 695-703, 2006.
38. M. Modarai, J. Gertsch, A. Suter, M. Heinrich, and A. Kortenkamp, "Cytochrome P450 inhibitory action of Echinacea preparations differs widely and co-varies with alkylamide content, " Journal of Pharmacy and Pharmacology, vol. 59, no. 4, pp. 567-573, 2007.
39. S. R. Penzak, S. M. Robertson, J. D. Hunt et al., "Echinacea purpurea significantly induces cytochrome P450 3A activity but does not alter Lopinavir-Ritonavir exposure in healthy subjects, " Pharmacotherapy, vol. 30, no. 8, pp. 797-805, 2010.
40. A. K. L. Goey, I. Meijerman, H. Rosing et al., "The effect of echinacea purpurea on the pharmacokinetics of docetaxel, " British Journal of Clinical Pharmacology, vol. 76, no. 3, pp. 467-474, 2013.
41. CAM-CANCER, Echinacea spp, 2015, http://www. cam-cancer. org/CAM-Summaries/Herbal-products/Echinacea-spp/Doesit-work.
42. J. T. Giles, C. T. Palat III, S. H. Chien, Z. G. Chang, and D. T. Kennedy, "Evaluation of echinacea for treatment of the common cold, " Pharmacotherapy, vol. 20, no. 6 I, pp. 690-697, 2000.
43. S. E. Edwards, I. C. Rocha, E. M. Williamson, and M. Heinrich, Phytopharmacy: An Evidence-Based Guide to Herbal Medicinal Products, JohnWiley & Sons, 2015.
44. B. Mukherjee, N. Telang, and G. Y. C. Wong, "Growth inhibition of estrogen receptor positive human breast cancer cells by Taheebo from the inner bark of Tabebuia avellandae tree, " International Journal of Molecular Medicine, vol. 24, no. 2, pp. 253-260, 2009.
45. J. J. Pink, S. Wuerzberger-Davis, C. Tagliarino et al., "Activation of a cysteine protease in MCF-7 and T47D breast cancer cells during β-lapachone-mediated apoptosis, " Experimental Cell Research, vol. 255, no. 2, pp. 144-155, 2000.
46. J. R. Gómez Castellanos, J. M. Prieto, and M. Heinrich, "Red Lapacho (Tabebuia impetiginosa)-A global ethnopharmacological commodity?" Journal of Ethnopharmacology, vol. 121, no. 1, pp. 1-13, 2009.
47. K. J. Ahn, H. S. Lee, S. K. Bai, and C. W. Song, "Enhancement of radiation effect using beta-lapachone and underlying mechanism, " RadiationOncology Journal, vol. 31, no. 2, pp. 57-65, 2013.
48. C. Tagliarino, J. J. Pink, G. R. Dubyak, A.-L. Nieminenll, and D. A. Boothman, "Calcium Is a Key Signaling Molecule in β-lapachone-mediated Cell Death, " Journal of Biological Chemistry, vol. 276, no. 22, pp. 19150-19159, 2001.
49. M.-T. Lin, C.-C. Chang, S.-T. Chen et al., "Cyr61 expression confers resistance to apoptosis in breast cancerMCF-7 cells by a mechanism of NF-kB-dependent XIAP up-regulation, " Journal of Biological Chemistry, vol. 279, no. 23, pp. 24015-24023, 2004.
50. H. J. Park, K.-J. Ahn, S.-D. Ahn et al., "Susceptibility of cancer cells to beta-lapachone is enhanced by ionizing radiation, " International Journal of Radiation Oncology, Biology, Physics, vol. 61, no. 1, pp. 212-219, 2005.
51. E. A. Bey, K. E. Reinicke, M. C. Srougi et al., "Catalase abrogates β-lapachone-induced PARP1 hyperactivation-directed programmed necrosis in NQO1-positive breast cancers, " Molecular Cancer Therapeutics, vol. 12, no. 10, pp. 2110-2120, 2013.
52. H. Kung, K. S. Lu, and Y. P. Chau, "The chemotherapeutic effects of lapacho tree extract: β-lapachone, " Chemotherapy, vol. 3, no. 2, pp. 131-135, 2014.
53. O. A. Lemos, J. C. M. Sanches, I. E. F. Silva et al., "Genotoxic effects of Tabebuia impetiginosa (Mart. Ex DC.) Standl. (Lamiales, Bignoniaceae) extract in Wistar rats, " Genetics and Molecular Biology, vol. 35, no. 2, pp. 498-502, 2012.
54. C. K. Wong, Y. X. Bao, E. L. Wong, P. C. Leung, K. P. Fung, and C. W. Lam, "Immunomodulatory activities ofYunzhi andDanshen in post-treatment breastcancer patients, " The American Journal of Chinese Medicine, vol. 33, no. 3, pp. 381-395, 2005.
55. J. Chen, Q. Lv, M. Yu, X. Zhang, and J. Gou, "Randomized clinical trial of Chinese herbal medications to reduce wound complications after mastectomy for breast carcinoma, " British Journal of Surgery, vol. 97, no. 12, pp. 1798-1804, 2010.
56. C. Santos Araujo Mdo, I. L. Farias, J. Gutierres et al., "Uncaria tomentosa-adjuvant treatment for breast cancer: clinical trial, " Evidence-Based Complementary and Alternative Medicine, vol. 2012, Article ID 676984, 8 pages, 2012.
57. A. Pourzand, A. Tajaddini, S. Pirouzpanah et al., "Associations between dietary alliumvegetables and risk of breast cancer: A hospital-based matched case-control study, " Journal of Breast Cancer, vol. 19, no. 3, pp. 292-300, 2016.
58. M. C. Cox, J. Low, J. Lee et al., "Influence of garlic (Allium sativum) on the pharmacokinetics of docetaxel, " Clinical Cancer Research, vol. 12, no. 15, pp. 4636-4640, 2006.
59. E. C. Lowcock, M. Cotterchio, and B. A. Boucher, "Consumption of flaxseed, a rich source of lignans, is associated with reduced breast cancer risk, " Cancer Causes and Control, vol. 24, no. 4, pp. 813-816, 2013.
60. G. Lindahl, N. Saarinen, A. Abrahamsson, and C. Dabrosin, "Tamoxifen, flaxseed, and the lignan enterolactone increase stroma-and cancer cell-derived IL-1Ra and decrease tumor angiogenesis in estrogen-dependent breast cancer, " Cancer Research, vol. 71, no. 1, pp. 51-60, 2011.
61. U. W. Nilsson ?Aberg, N. Saarinen, A. Abrahamsson, T. Nurmi, S. Engblom, and C. Dabrosin, "Tamoxifen and flaxseed alter angiogenesis regulators in normal human breast tissue in vivo, " PLoS ONE, vol. 6, no. 9, Article ID e25720, 2011.
62. S. E. McCann, S. B. Edge, D. G. Hicks et al., "A pilot study comparing the effect of flaxseed, aromatase inhibitor, and the combination on breast tumor biomarkers, " Nutrition and Cancer, vol. 66, no. 4, pp. 566-575, 2014.
63. K. Buck, A. K. Zaineddin, A. Vrieling et al., "Estimated enterolignans, lignan-rich foods, and fibre in relation to survival after postmenopausal breast cancer, " British Journal of Cancer, vol. 105, no. 8, pp. 1151-1157, 2011.
64. M. Bayet-Robert, F. Kwiatowski, M. Leheurteur et al., "Phase I dose escalation trial of docetaxel plus curcumin in patients with advanced and metastatic breast cancer, " Cancer Biology & Therapy, vol. 9, no. 1, pp. 8-14, 2010.
65. Y.-F. Zhang, Q. Xu, J. Lu et al., "Tea consumption and the incidence of cancer: A systematic review and meta-analysis of prospective observational studies, " European Journal of Cancer Prevention, vol. 24, no. 4, pp. 353-362, 2015.
66. M. Iwasaki, M. Inoue, S. Sasazuki et al., "Green tea drinking and subsequent risk of breast cancer in a population to based cohort of Japanese women, " Breast Cancer Research, vol. 12, no. 5, article no. R88, 2010.
67. M. Zhang, C. D. J. Holman, J.-P. Huang, and X. Xie, "Green tea and the prevention of breast cancer: A case-control study in Southeast China, " Carcinogenesis, vol. 28, no. 5, pp. 1074-1078, 2007.
68. M. Iwasaki, M. Inoue, S. Sasazuki et al., "Plasma tea polyphenol levels and subsequent risk of breast cancer among Japanese women: A nested case-control study, " Breast Cancer Research and Treatment, vol. 124, no. 3, pp. 827-834, 2010.
69. J. Luo, Y.-T. Gao, W.-H. Chow et al., "Urinary polyphenols and breast cancer risk: results from the Shanghai Women's Health Study, " Breast Cancer Research and Treatment, vol. 120, no. 3, pp. 693-702, 2010.
70. K. D. Crew, K. A. Ho, P. Brown et al., "Effects of a green tea extract, Polyphenon E, on systemic biomarkers of growth factor signalling in women with hormone receptor-negative breast cancer, " Journal of Human Nutrition and Dietetics, vol. 28, no. 3, pp. 272-282, 2015.
71. J.-M. Yuan, W.-P. Koh, C.-L. Sun, H.-P. Lee, and M. C. Yu, "Green tea intake, ACE gene polymorphism and breast cancer risk among Chinese women in Singapore, " Carcinogenesis, vol. 26, no. 8, pp. 1389-1394, 2005.
72. M. Inoue-Choi, J. M. Yuan, Yang C. S. et al., "Genetic association between the COMT genotype and urinary levels of tea polyphenols and their metabolites among daily green tea drinkers, " International Journal of Molecular Epidemiology and Genetics, vol. 1, no. 2, pp. 114-123, 2010.
73. A. H. Wu, Tseng C. C., D. Van Den Berg, and M. C. Yu, "Tea intake, COMT genotype, and breast cancer in Asian-American women, " Cancer Research, vol. 63, no. 21, pp. 7526-7529, 2003.
74. G. Zhang, Y. Wang, Y. Zhang et al., "Anti-cancer activities of tea epigallocatechin-3-gallate in breast cancer patients under radiotherapy, " Current Molecular Medicine, vol. 12, no. 2, pp. 163-176, 2012.
75. A. M. Dostal, H. Samavat, S. Bedell et al., "The safetyof green tea extract supplementation in postmenopausal women at risk for breast cancer: results of the Minnesota Green Tea Trial, " Food and Chemical Toxicology, vol. 83, pp. 26-35, 2015.
76. M. Lazzeroni, A. Guerrieri-Gonzaga, S. Gandini et al., "A presurgical study of lecithin formulation of green tea extract inwomen with early breast cancer, " Cancer Prevention Research (Phila), vol. 10, no. 6, pp. 363-370, 2017.
77. D. Seely, E. J. Mills, P. Wu, S. Verma, and G. H. Guyatt, "The effects of green tea consumption on incidence of breast cancer and recurrence of breast cancer: A systematic review andmetaanalysis, " Integrative CancerTherapies, vol. 4, no. 2, pp. 144-155, 2005.
78. J. W. Liu, S. Liangxin, Z. Yi et al., "Clinical phase II study on immunoimprovement of patients with breast cancer treated by Shengyi capsule, " Chinese Journal of Clinical Oncology, vol. 27, pp. 534-544, 2000.
79. P.-P. Bao, W. Lu, Y. Cui et al., "Ginseng and Ganoderma lucidum use after breast cancer diagnosis and quality of life: A report from the Shanghai breast cancer survival study, " PLoS ONE, vol. 7, no. 6, Article ID e39343, 2012.
80. Y. Cui, X.-O. Shu, Y.-T. Gao, H. Cai, M.-H. Tao, and W. Zheng, "Association of ginseng use with survival and quality of life among breast cancer patients, " American Journal of Epidemiology, vol. 163, no. 7, pp. 645-653, 2006.
81. H. Fritz, D. Seely, J. McGowan et al., "Black cohosh and breast cancer: A systematic review, " Integrative Cancer Therapies, vol. 13, no. 1, pp. 12-29, 2014.
82. H. H. Henneicke-von Zepelin, H. Meden, K. Kostev, D. Schröder-Bernhardi, U. Stammwitz, and H. Becher, "Isopropanolic black cohosh extract and recurrence-free survival after breast cancer, " Int. Journal of Clinical Pharmacology and Therapeutics, vol. 45, no. 3, pp. 143-154, 2007.
83. S. Roy, "Breast Tumour Regression using Mistletoe Extract: An evidence from an Indian Clinic, " Helix, vol. 1, pp. 651-655, 2015.
84. W. Tröger, Z. Zdrale, N. Ti?sma, and M. Matija?sevíc, "Additional therapy with a mistletoe product during adjuvant chemotherapy of breast cancer patients improves quality of life: An open randomized clinical pilot trial, " Evidence-Based Complementary and Alternative Medicine, vol. 2014, Article ID 430518, 9 pages, 2014.
85. W. Tröger, Z. ?Zdrale, N. Stankovíc, and M. Matija?sevíc, "Fiveyear follow-up of patients with early stage breast cancer after a randomized study comparing additional treatment with Viscum album (L.) extract to chemotherapy alone, " Breast Cancer: Basic and Clinical Research, vol. 6, no. 1, pp. 173-180, 2012.
86. J. Eisenbraun, R. Scheer, M. Kröz, F. Schad, and R. Huber, "Quality of life in breast cancer patients during chemotherapy and concurrent therapy with a mistletoe extract, " Phytomedicine, vol. 18, no. 2-3, pp. 151-157, 2011.
87. A. Büssing, U. Brückner, and U. Enser-Weis, "Modulation of chemotherapy-associated immunosuppression by intravenous application of Viscum album L. extract (Iscador): A randomised phase II study, " European Journal of Integrative Medicine, vol. 1, pp. 2-3, 2008.
88. J. Beuth, B. Schneider, and J. M. Schierholz, "mpact of complementary treatment of breast cancer patients with standardized mistletoe extract during aftercare: A controlled multicenter comparative epidemiological cohort study, " Anticancer Research, vol. 28, no. 1B, pp. 523-527, 2008.
89. A. C. Gören, T. Kiliç, T. Dirmenci, and G. Bilsel, "Chemotaxonomic evaluation of Turkish species of Salvia: Fatty acid compositions of seed oils, " Biochemical Systematics and Ecology, vol. 34, no. 2, pp. 160-164, 2006.
90. R. Abu-Dahab, F. Afifi, V. Kasabri, L. Majdalawi, and R. Naffa, "Comparison of the antiproliferative activity of crude ethanol extracts of nine salvia species grown in Jordan against breast cancer cell line models, " Pharmacognosy Magazine, vol. 8, no. 32, pp. 319-324, 2012.
91. R. Abu-Dahab, M. R. Abdallah, V. Kasabri, N. M. Mhaidat, and F. U. Afifi, "Mechanistic studies of antiproliferative effects of salvia triloba and salvia dominica (Lamiaceae) on breast cancer cell lines (MCF7 and T47D), " Zeitschrift fürNaturforschung, vol. 69c, pp. 443-451, 2015.
92. W. Yang, J.-H. Ju, M. J. Jeon, X. Han, and I. Shin, "Danshen (Salvia miltiorrhiza) extract inhibits proliferation of breast cancer cells via modulation of akt activity and p27 level, " Phytotherapy Research, vol. 24, no. 2, pp. 198-204, 2010.
93. J. Baselga, E. A. Perez, T. Pienkowski, and R. Bell, "Adjuvant trastuzumab: A milestone in the treatment of HER-2-positive early breast cancer, " Oncologist, vol. 11, no. 1, pp. 4-12, 2006.
94. M. Dowsett, "Overexpression of HER-2 as a resistance mechanism to hormonal therapy for breast cancer, " Endocrine-Related Cancer, vol. 8, no. 3, pp. 191-195, 2001.
95. X. Wang, Y. Wei, S. Yuan et al., "Potential anticancer activity of tanshinone IIA against human breast cancer, " International Journal of Cancer, vol. 116, no. 5, pp. 799-807, 2005.
96. X. Wang, K. F. Bastow, C.-M. Sun et al., "Antitumor agents. 239. Isolation, structure elucidation, total synthesis, and anti-breast cancer activity of neo-tanshinlactone from Salvia miltiorrhiza, " Journal of Medicinal Chemistry, vol. 47, no. 23, pp. 5816-5819, 2004.
97. I. T. Nizamutdinova, G. W. Lee, K. H. Son et al., "Tanshinone I effectively induces apoptosis in estrogen receptor-positive (MCF-7) and estrogen receptor-negative(MDA-MB-231) breast cancer cells, " International Journal ofOncology, vol. 33, no. 3, pp. 485-491, 2008.
98. Y. Gong, Y. Li, H. M. Abdolmaleky, L. Li, and J.-R. Zhou, "Tanshinones inhibit the growth of breast cancer cells through epigenetic modification of aurora a expression and function, " PLoS ONE, vol. 7, no. 4, Article ID e33656, 2012.
99. V. Nicolin, G. Fancellu, and R. Valentini, "Effect of tanshinone II on cell growth of breast cancer cell line typeMCF-7 and MDMB-231, " Italian Journal of Anatomy and Embryology, vol. 119, no. 1, pp. 38-43, 2014.
100. J. Cai, S. Chen, W. Zhang et al., "Salvianolic acid A reverses paclitaxel resistance in human breast cancer MCF-7 cells via targeting the expression of transgelin 2 and attenuating PI3 K/Akt pathway, " Phytomedicine, vol. 21, no. 12, pp. 1725-1732, 2014.
101. P. Fu, F. Du, W. Chen, M. Yao, K. Lv, and Y. Liu, "Tanshinone IIA blocks epithelial-mesenchymal transition through HIF-1α downregulation, reversing hypoxia-induced chemotherapy resistance in breast cancer cell lines, " Oncology Reports, vol. 31, no. 6, pp. 2561-2568, 2014.
102. L. Riva, D. Coradini, G. Di Fronzo et al., "The antiproliferative effects of Uncaria tomentosa extracts and fractions on the growth of breast cancer cell line, " Anticancer Research, vol. 21, no. 4A, pp. 2457-2461, 2001.
103. CAM-CANCER, Cat's Claw (Uncaria spp), 2015, http://www. cam-cancer. org/CAM-Summaries/Herbal-products/Cat-s-claw-Uncaria-spp/What-is-it.
104. S. Y. Pan, J. Zhou, L. Gibbons, H. Morrison, and S. W. Wen, "Antioxidants and breast cancer risk-A population-based casecontrol study in Canada, " BMC Cancer, vol. 11, article no. 372, 2011.
105. S. C. Larsson, A. ?Akesson, L. Bergkvist, and A. Wolk, "Multivitamin use and breast cancer incidence in a prospective cohort of Swedish women, " American Journal of Clinical Nutrition, vol. 91, no. 5, pp. 1268-1272, 2010.
106. J. M. Meulepas, P. A. Newcomb, A. N. Burnett-Hartman, J. M. Hampton, and A. Trentham-Dietz, "Multivitamin supplement use and risk of invasive breast cancer, " Public Health Nutrition, vol. 13, no. 10, pp. 1540-1545, 2010.
107. P. G. Moorman, M. F. Ricciuti, R. C. Millikan, and B. Newman, "Vitamin supplement use and breast cancer in aNorth Carolina population, " Public Health Nutrition, vol. 4, no. 3, pp. 821-827, 2001.
108. C. Wang, R. N. Baumgartner, D. Yang et al., "No evidence of association between breast cancer risk and dietary carotenoids, retinols, vitamin C and tocopherols in Southwestern Hispanic and non-hispanic white women, " Breast Cancer Research and Treatment, vol. 114, no. 1, pp. 137-145, 2009.
109. G. Nagel, J. Linseisen, C. H. van Gils et al., "Dietary betacarotene, vitamin C and E intake and breast cancer risk in the European prospective investigation into cancer and nutrition (EPIC), " Breast Cancer Research and Treatment, vol. 119, pp. 753-765, 2010.
110. A. Pantavos, R. Ruiter, E. F. Feskens et al., "Total dietary antioxidant capacity, individual antioxidant intake and breast cancer risk: The Rotterdam study, " International Journal of Cancer, vol. 136, no. 9, pp. 2178-2186, 2015.
111. S. Wassertheil-Smoller, A. P. McGinn, N. Budrys et al., "Multivitamin and mineral use and breast cancer mortality in older women with invasive breast cancer in the women's health initiative, " Breast Cancer Research and Treatment, vol. 141, no. 3, pp. 495-505, 2013.
112. E. M. Poole, X. Shu, B. J. Caan et al., "Postdiagnosis supplement use and breast cancer prognosis in the after Breast Cancer Pooling Project, " Breast Cancer Research and Treatment, vol. 139, no. 2, pp. 529-537, 2013.
113. M. L. Kwan, H. Greenlee, V. S. Lee et al., "Multivitamin use and breast cancer outcomes in women with early-stage breast cancer:The life after cancer epidemiology study, " Breast Cancer Research and Treatment, vol. 130, no. 1, pp. 195-205, 2011.
114. M. L. Lesperance, I. A. Olivotto, N. Forde et al., "Mega-dose vitamins and minerals in the treatment of non-metastatic breast cancer: An historical cohort study, " Breast Cancer Research and Treatment, vol. 76, no. 2, pp. 137-143, 2002.
115. F. Hu, Z. Wu, G. Li et al., "The plasma level of retinol, vitamins A, C and α-tocopherol could reduce breast cancer risk? A metaanalysis and meta-regression, " Journal of Cancer Research and Clinical Oncology, vol. 141, no. 4, pp. 601-614, 2015.
116. C. Pouchieu, P. Galan, V. Ducros, P. Latino-Martel, S. Hercberg, and M. Touvier, "Plasma carotenoids and retinol and overall and breast cancer risk: A nested case-control study, " Nutrition and cancer, vol. 66, no. 6, pp. 980-988, 2014.
117. L. I. Mignone, E. Giovannucci, P. A. Newcomb et al., "Dietary carotenoids and the risk of invasive breast cancer, " International Journal of Cancer, vol. 124, no. 12, pp. 2929-2937, 2009.
118. J. P. Huang, M. Jain, A. B. Miller, G. R. Howe, and T. E. Rohan, "Dietary carotenoids and risk of breast cancer in Chinese women, " Asia Pacific Journal of Clinical Nutrition, vol. 16, pp. 437-442, 2007.
119. G. C. Kabat, M. Kim, L. L. Adams-Campbell et al., "Longitudinal study of serum carotenoid, retinol, and tocopherol concentrations in relation to breast cancer risk among postmenopausal women, " American Journal of Clinical Nutrition, vol. 90, no. 1, pp. 162-169, 2009.
120. Y. Cui, J. M. Shikany, S. Liu, Y. Shagufta, and T. E. Rohan, "Selected antioxidants and risk of hormone receptor-defined invasive breast cancers among postmenopausal women in the women's health initiative observational study, " The American Journal of Clinical Nutrition, vol. 87, no. 4, pp. 1009-1018, 2008.
121. M. F. Bakker, P. H. Peeters, V. M. Klaasen et al., "Plasma carotenoids, vitamin C, tocopherols, and retinol and the risk of breast cancer in the European prospective investigation into cancer and nutrition cohort, " The American Journal of Clinical Nutrition, vol. 103, no. 2, pp. 454-464, 2016.
122. C. L. Rock, L. Natarajan, M. Pu et al., "Longitudinal biological exposure to carotenoids is associated with breast cancer-free survival in the women's healthy eating and living study, " Cancer Epidemiology Biomarkers and Prevention, vol. 18, no. 2, pp. 486-494, 2009.
123. J. Hutchinson, V. J. Burley, D. C. Greenwood, J. D. Thomas, and J. E. Cade, "High-dose vitamin C supplement use is associated with self-reported histories of breast cancer and other illnesses in the UKWomen's Cohort Study, " Public Health Nutrition, vol. 14, no. 5, pp. 768-777, 2010.
124. C. Cadeau, A. Fournier, S. Mesrine, F. Clavel-Chapelon, G. Fagherazzi, and M.-C. Boutron-Ruault, "Vitamin C supplement intake and postmenopausal breast cancer risk: Interaction with dietary vitamin C, " American Journal of Clinical Nutrition, vol. 104, no. 1, pp. 228-234, 2016.
125. H. R. Harris, L. Bergkvist, and A. Wolk, "Vitamin C intake and breast cancer mortality in a cohort of Swedish women, " British Journal of Cancer, vol. 109, no. 1, pp. 257-264, 2013.
126. H. R. Harris, N. Orsini, and A. Wolk, "Vitamin C and survival among women with breast cancer: A Meta-analysis, " European Journal of Cancer, vol. 50, no. 7, pp. 1223-1231, 2014.
127. J. Ramesh Babu, S. Sundravel, G. Arumugam, R. Renuka, N. Deepa, and P. Sachdanandam, "Salubrious effect of vitamin C and vitamin E on tamoxifen-treated women in breast cancer with reference to plasma lipid and lipoprotein levels, " Cancer Letters, vol. 151, no. 1, pp. 1-5, 2000.
128. N. Suhail, N. Bilal, H. Y. Khan et al., "Effect of vitamins C and e on antioxidant status of breast-cancer patients undergoing chemotherapy, " Journal of Clinical Pharmacy and Therapeutics, vol. 37, no. 1, pp. 22-26, 2012.
129. A. C. Carr, M. C. Vissers, and J. Cook, "Relief from cancer chemotherapy side effects with pharmacologic vitamin C, " New Zealand Medical Journal, vol. 127, no. 1388, pp. 66-70, 2014.
130. C. Vollbracht, B. Schneider, V. Leendert, G. Weiss, L. Auerbach, and J. Beuth, "Intravenous vitamin C administration improves quality of life in breast cancer patients during chemo-/radiotherapy and aftercare: results of a retrospective, multicentre, epidemiological cohort study in Germany, " In Vivo, vol. 25, no. 6, pp. 983-990, 2011.
131. M. Saintot, H. Mathieu-Daude, C. Astre, J. Grenier, J. Simony-Lafontaine, and M. Gerber, "Oxidant-antioxidant status in relation to survival among breast cancer patients, " International Journal of Cancer, vol. 97, no. 5, pp. 574-579, 2002.
132. E. A. Peralta, A. T. Brewer, S. Louis, and G. L. Dunnington, "Vitamin E Increases Biomarkers of Estrogen Stimulation WhenTakenWithTamoxifen, " Journal of Surgical Research, vol. 153, no. 1, pp. 143-147, 2009.
133. M. Magnusson, P. Höglund, K. Johansson et al., "Pentoxifylline and vitamin E treatment for prevention of radiation-induced side-effects in women with breast cancer: A phase two, doubleblind, placebo-controlled randomised clinical trial (Ptx-5), " European Journal of Cancer, vol. 45, no. 14, pp. 2488-2495, 2009.
134. S. Delanian, R. Porcher, S. Balla-Mekias, and J.-L. Lefaix, "Randomized, placebo-controlled trial of combined pentoxifylline and tocopherol for regression of superficial radiation-induced fibrosis, " Journal of Clinical Oncology, vol. 21, no. 13, pp. 2545-2550, 2003.
135. L. Teleni, J. Baker, B. Koczwara et al., "Clinical outcomes of vitamin D deficiency and supplementation in cancer patients, " Nutrition Reviews, vol. 71, no. 9, pp. 611-621, 2013.
136. F. Sperati, P. Vici, M. Maugeri-Saccà et al., "Vitamin D Supplementation and Breast Cancer Prevention: A Systematic Review and Meta-Analysis of Randomized Clinical Trials, " PLoS ONE, vol. 8, no. 7, Article ID e69269, 2013.
137. S. B. Mohr, E. D. Gorham, J. E. Alcaraz et al., "Serum 25-hydroxyvitamin D and breast cancer in the military: A casecontrol study utilizing pre-diagnostic serum, " Cancer Causes and Control, vol. 24, no. 3, pp. 495-504, 2013.
138. K. Edvardsen, M. B. Veierød, M. Brustad, T. Braaten, O. Engelsen, and E. Lund, "Vitamin D-effective solarUVradiation, dietary vitamin D and breast cancer risk, " International Journal of Cancer, vol. 128, no. 6, pp. 1425-1433, 2011.
139. S. C. Larsson, L. Bergkvist, and A. Wolk, "Long-term dietary calcium intake and breast cancer risk in a prospective cohort of women, " American Journal of Clinical Nutrition, vol. 89, no. 1, pp. 277-282, 2009.
140. S. M. Boyapati, X. O. Shu, F. Jin et al., "Dietary calcium intake and breast cancer risk among Chinese women in Shanghai, " Nutrition and Cancer, vol. 46, no. 1, pp. 38-43, 2003.
141. S. Abbas, J. Linseisen, S. Rohrmann et al., "Dietary Intake of VitaminDandCalciumand BreastCancer Risk in the European Prospective Investigation into Cancer and Nutrition, " Nutrition and Cancer, vol. 65, no. 2, pp. 178-187, 2013.
142. L. N. Anderson, M. Cotterchio, R. Vieth, and J. A. Knight, "Vitamin D and calcium intakes and breast cancer risk in pre-and postmenopausal women, "American Journal of Clinical Nutrition, vol. 91, no. 6, pp. 1699-1707, 2010.
143. T. E. Rohan, A. Negassa, R. T. Chlebowski et al., "A randomized controlled trial of calcium plus vitamin D supplementation and risk of benign proliferative breast disease, " Breast Cancer Research and Treatment, vol. 116, no. 2, pp. 339-350, 2009.
144. R. T. Chlebowski, Johnson K. C., C. Kooperberg et al., "Calcium plus Vitamin D supplementation and the risk of breast cancer, " Journal of theNational Cancer Institute, vol. 100, no. 22, pp. 1581-1591, 2008.
145. S. Scarmo, Y. Afanasyeva, P. Lenner et al., "Circulating levels of 25-hydroxyvitamin D and risk of breast cancer: A nested casecontrol study, " Breast Cancer Research, vol. 15, no. 1, article no. R15, 2013.
146. A. H. Eliassen, D. Spiegelman, B. W. Hollis, R. L. Horst, W. C. Willett, and S. E. Hankinson, "Plasma 25-hydroxyvitamin D and risk of breast cancer in the Nurses' Health Study II, " Breast Cancer Research, vol. 13, no. 3, article no. R50, 2011.
147. B. L. Sprague, H. G. Skinner, A. Trentham-Dietz, K. E. Lee, B. E. K. Klein, and R. Klein, "Serum Calciumand Breast Cancer Risk in a Prospective Cohort Study, " Annals of Epidemiology, vol. 20, no. 1, pp. 82-85, 2010.
148. J. Li, W.-P. Koh, A.-Z. Jin, J.-M. Yuan, M. C. Yu, and L. M. Butler, "Calcium intake is not related to breast cancer risk among SingaporeChinesewomen, " International Journal ofCancer, vol. 133, no. 3, pp. 680-686, 2013.
149. C.-X. Zhang, S. C. Ho, J.-H. Fu, S.-Z. Cheng, Y.-M. Chen, and F.-Y. Lin, "Dairy products, calcium intake, and breast cancer risk: A case-control study in China, " Nutrition and Cancer, vol. 63, no. 1, pp. 12-20, 2011.
150. P. Engel, G. Fagherazzi, A. Boutten et al., "Serum 25(OH) vitaminDand risk of breast cancer: A nested case-control study from the French E3N cohort, " Cancer Epidemiology Biomarkers and Prevention, vol. 19, no. 9, pp. 2341-2350, 2010.
151. E. Kesse-Guyot, S. Bertrais, B. Duperray et al., "Dairy products, calcium and the risk of breast cancer: Results of the French SU. VI. MAX prospective study, " Annals of Nutrition and Metabolism, vol. 51, no. 2, pp. 139-145, 2007.
152. P. Engel, G. Fagherazzi, S. Mesrine, M.-C. Boutron-Ruault, and F. Clavel-Chapelon, "Joint effects of dietary vitamin d and sun exposure on breast cancer risk: Results from the French E3N cohort, " Cancer Epidemiology Biomarkers and Prevention, vol. 20, no. 1, pp. 187-195, 2011.
153. M. Rossi, J. K. McLaughlin, P. Lagiou et al., "Vitamin D intake and breast cancer risk: A case-control study in Italy, " Annals of Oncology, vol. 20, no. 2, pp. 374-378, 2009.
154. U. Shamsi, S. Khan, S. Usman, S. Soomro, and I. Azam, "A multicenter matched case control study of breast cancer risk factors among women in Karachi, Pakistan, " Asian Pacific Journal of Cancer Prevention, vol. 14, no. 1, pp. 183-188, 2013.
155. M.-S. Lee, Y.-C. Huang, M. L. Wahlqvist et al., "Vitamin d decreases risk of breast cancer in premenopausal women of normal weight in subtropical Taiwan, " Journal of Epidemiology, vol. 21, no. 2, pp. 87-94, 2011.
156. K. Bilinski and J. Boyages, "Association between 25-hydroxyvitamin D concentration and breast cancer risk in an Australian population: An observational case-control study, " Breast Cancer Research and Treatment, vol. 137, no. 2, pp. 599-607, 2013.
157. P. Chen, P. Hu, D. Xie, Y. Qin, F. Wang, and H. Wang, "Metaanalysis of vitamin D, calcium and the prevention of breast cancer, " Breast Cancer Research and Treatment, vol. 121, no. 2, pp. 469-477, 2010.
158. T. Kawase, K. Matsuo, T. Suzuki et al., "Association between vitamin D and calcium intake and breast cancer risk according to menopausal status and receptor status in Japan, " Cancer Science, vol. 101, no. 5, pp. 1234-1240, 2010.
159. M. Deschasaux, J.-C. Souberbielle, P. Latino-Martel et al., "Weight status and alcohol intake modify the association between vitamin D and breast cancer risk, " Journal of Nutrition, vol. 146, no. 3, pp. 576-585, 2016.
160. A. H. Eliassen, E. T. Warner, B. Rosner et al., "Plasma 25-hydroxyvitamin D and risk of breast cancer in women followed over 20 years, " Cancer Research, vol. 76, no. 18, pp. 5423-5430, 2016.
161. Y. Jamshidinaeini, M. E. Akbari, M. Abdollahi, M. Ajami, and S. H. Davoodi, "Vitamin D Status and Risk of Breast Cancer in Iranian Women: A Case-Control Study, " Journal of the American College of Nutrition, vol. 35, no. 7, pp. 639-646, 2016.
162. S. Park, D. H. Lee, J. Y. Jeon et al., "Serum 25-hydroxyvitamin D deficiency and increased risk of breast cancer among Korean women: A case-control study, " Breast Cancer Research and Treatment, vol. 152, no. 1, pp. 147-154, 2015.
163. Y. Kim, A. A. Franke, Y. B. Shvetsov et al., "Plasma 25-hydroxyvitamin D3 is associated with decreased risk of postmenopausal breast cancer inwhites:Anested case-control study in the multiethnic cohort study, " BMC Cancer, vol. 14, no. 1, article no. 29, 2014.
164. K. D. Crew, M. D. Gammon, S. E. Steck et al., "Association between plasma 25-hydroxyvitamin D and breast cancer risk, " Cancer Prevention Research, vol. 2, no. 6, pp. 598-604, 2009.
165. T. Kuhn, R. Kaaks, S. Becker et al., "Plasma 25-hydroxyvitamin D and the risk of breast cancer in the European prospective investigation into cancer and nutrition: A nested case-control study, " International Journal of Cancer, vol. 133, no. 7, pp. 1689-1700, 2013.
166. S. Abbas, J. Chang-Claude, and J. Linseisen, "Plasma 25-hydroxyvitamin D and premenopausal breast cancer risk in a German case-control study, " International Journal of Cancer, vol. 124, no. 1, pp. 250-255, 2009.
167. C. M. N. Oliveira-Sediyama, M. M. Dos Santos Dias, M. C. Pessoa et al., "Lifestyle and vitamin D dosage in women with breast cancer, " Nutricion Hospitalaria, vol. 33, no. 5, pp. 1179-1186, 2016.
168. S. R. Bauer, S. E. Hankinson, E. R. Bertone-Johnson, and E. L. Ding, "Plasma vitamin d levels, menopause, and risk of breast cancer: dose-response meta-analysis of prospective studies, " Medicine, vol. 92, no. 3, pp. 123-131, 2013.
169. M. Almquist, J. Manjer, L. Bondeson, and A.-G. Bondeson, "Serum calcium and breast cancer risk: Results froma prospective cohort study of 7, 847 women, " Cancer Causes and Control, vol. 18, no. 6, pp. 595-602, 2007.
170. D. Wang, O. I. Vélez De-La-Paz, J.-X. Zhai, and D.-W. Liu, "Serum 25-hydroxyvitamin D and breast cancer risk: A metaanalysis of prospective studies, " Tumor Biology, vol. 34, no. 6, pp. 3509-3517, 2013.
171. W. Wulaningsih, H. K. Sagoo, M. Hamza et al., "Serumcalcium and the risk of breast cancer: Findings from the Swedish AMORIS study and a meta-analysis of prospective studies, " International Journal of Molecular Sciences, vol. 17, no. 9, article no. 1487, 2016.
172. L. Huss, S. Butt, S. Borgquist, M. Almquist, J. Malm, and J. Manjer, "Serum levels of vitamin D, parathyroid hormone and calcium in relation to survival following breast cancer, " Cancer Causes and Control, vol. 25, no. 9, pp. 1131-1140, 2014.
173. L. Shirazi, M. Almquist, S. Borgquist, J. Malm, and J. Manjer, "Serum vitamin D (25OHD3) levels and the risk of different subtypes of breast cancer: A nested case-control study, " Breast, vol. 28, pp. 184-190, 2016.
174. J. D. McKay, M. L. McCullough, R. G. Ziegler et al., "Vitamin D receptor polymorphisms and breast cancer risk: results from the national cancer institute breast and prostate cancer cohort consortium, " Cancer Epidemiology, Biomarkers & Prevention, vol. 18, no. 1, pp. 197-305, 2009.
175. J. Shi, A. Grundy, H. Richardson et al., "Genetic variation in vitamin D-related genes and risk of breast cancer amongwomen of European and East Asian descent, " Tumor Biology, vol. 37, no. 5, pp. 6379-6387, 2016.
176. D. E. Rollison, A. L. Cole, K.-H. Tung et al., "Vitamin D intake, vitamin D receptor polymorphisms, and breast cancer risk among women living in the southwestern U. S., " Breast Cancer Research and Treatment, vol. 132, no. 2, pp. 683-691, 2012.
177. H. J. Kim, Y. M. Lee, B. S. Ko et al., "Vitamin D deficiency is correlated with poor outcomes in patients with luminal-type breast cancer, " Annals of Surgical Oncology, vol. 18, no. 7, pp. 1830-1836, 2011.
178. B. Trabert, K. E. Malone, J. R. Daling et al., "Vitamin D receptor polymorphisms and breast cancer risk in a large populationbased case-control study of Caucasian and African-American women, " Breast Cancer Research, vol. 9, no. 6, p. R84, 2007.
179. E. T. Jacobs, C. A. Thomson, S. W. Flatt et al., "Vitamin D and breast cancer recurrence in the Women's Healthy Eating and Living (WHEL) Study, " American Journal of Clinical Nutrition, vol. 93, no. 1, pp. 108-117, 2011.
180. M. A. Tao, Q. Dai, A. E. Millen et al., "Associations of intakes of magnesium and calcium and survival among women with breast cancer: results from western New York exposures and breast cancer (WEB) study, " Cancer Research, vol. 6, no. 1, pp. 105-113, 2015.
181. P. J. Goodwin, M. Ennis, K. I. Pritchard, J. Koo, and N. Hood, "Prognostic effects of 25-hydroxy vitamin D levels in early breast cancer, " Journal of Clinical Oncology, vol. 27, no. 23, pp. 3757-3763, 2009.
182. A. Villaseñor, R. Ballard-Barbash, A. Ambs et al., "Associations of serum 25-hydroxyvitamin D with overall and breast cancerspecific mortality in a multiethnic cohort of breast cancer survivors, " Cancer Causes and Control, vol. 24, no. 4, pp. 759-767, 2013.
183. L. J. Peppone, A. S. Rickles, M. C. Janelsins, M. R. Insalaco, and K. A. Skinner, "The association between breast cancer prognostic indicators and serum 25-OH vitamin D levels, " Annals of Surgical Oncology, vol. 19, no. 8, pp. 2590-2599, 2012.
184. S. Yao, L. E. Sucheston, A. E. Millen et al., "Pretreatment serum concentrations of 25-hydroxyvitamin D and breast cancer prognostic characteristics: A case-control and a case-series study, " PLoS ONE, vol. 6, no. 2, Article ID e17251, 2011.
185. M. Almquist, L. Anagnostaki, L. Bondeson et al., "Serum calcium and tumour aggressiveness in breast cancer:Aprospective study of 7847 women, " European Journal of Cancer Prevention, vol. 18, no. 5, pp. 354-360, 2009.
186. K. D. Crew, E. Shane, S. Cremers, D. J. McMahon, D. Irani, and D. L. Hershman, "High prevalence of vitamin D deficiency despite supplementation in premenopausal women with breast cancer undergoing adjuvant chemotherapy, " Journal of Clinical Oncology, vol. 27, no. 13, pp. 2151-2156, 2009.
187. A. C. Shapiro, S. A. Adlis, K. Robien et al., "Randomized, blinded trial of vitamin D3 for treating aromatase inhibitorassociated musculoskeletal symptoms (AIMSS), " Breast Cancer Research and Treatment, vol. 155, no. 3, pp. 501-512, 2016.
188. E. Amir, C. E. Simmons, O. C. Freedman et al., "A phase 2 trial exploring the effects of high-dose (10, 000 IU/day) vitamin D3 in breast cancer patients with bone metastases, " Cancer, vol. 116, no. 2, pp. 284-291, 2010.
189. M. Datta and G. G. Schwartz, "Calcium and vitamin D supplementation and loss of bone mineral density in women undergoing breast cancer therapy, " Critical Reviews in Oncology/ Hematology, vol. 88, no. 3, pp. 613-624, 2013.
190. Q. J. Khan, P. S. Reddy, B. F. Kimler et al., "Effect of vitamin D supplementation on serum 25-hydroxy vitamin D levels, joint pain, and fatigue in women starting adjuvant letrozole treatment for breast cancer, " Breast Cancer Research and Treatment, vol. 119, no. 1, pp. 111-118, 2010.
191. A. L. Rastelli, M. E. Taylor, F. Gao et al., "Vitamin D and aromatase inhibitor-inducedmusculoskeletal symptoms (AIMSS): A phase II, double-blind, placebo-controlled, randomized trial, " Breast Cancer Research and Treatment, vol. 129, no. 1, pp. 107-116, 2011.
192. S. Arul Vijaya Vani, P. H. Ananthanarayanan, D. Kadambari, K. T. Harichandrakumar, R. Niranjjan, and H. Nandeesha, "Effects of vitamin D and calcium supplementation on side effects profile in patients of breast cancer treatedwith letrozole, " Clinica Chimica Acta, vol. 459, pp. 53-56, 2016.
193. D. Prieto-Alhambra, M. K. Javaid, S. Servitja et al., "Vitamin D threshold to prevent aromatase inhibitor-induced arthralgia: A prospective cohort study, " Breast Cancer Research and Treatment, vol. 125, no. 3, pp. 869-878, 2011.
194. D. Prieto-Alhambra, S. Servitja, M. K. Javaid et al., "Vitamin D threshold to prevent aromatase inhibitor-related bone loss: The B-ABLE prospective cohort study, " Breast Cancer Research and Treatment, vol. 133, no. 3, pp. 1159-1167, 2012.
195. S. J. Kim, A. Zuchniak, K.-J. Sohn et al., "Plasma folate, Vitamin B-6, and Vitamin B-12 and breast cancer risk in BRCA1-And BRCA2-mutation carriers: A prospective study, " American Journal of Clinical Nutrition, vol. 104, no. 3, pp. 671-677, 2016.
196. S. M. Zhang, N. R. Cook, C. M. Albert, J. M. Gaziano, J. E. Buring, and J. E. Manson, "Effect of combined folic acid, vitamin B6, and vitamin B12 on cancer risk in women. A randomized trial, " The Journal of the AmericanMedical Association, vol. 300, pp. 2012-2021, 2008.
197. M. Liu, L.-H. Cui, A.-G. Ma, N. Li, and J.-M. Piao, "Lack of effects of dietary folate intake on risk of breast cancer: An updated meta-analysis of prospective studies, " Asian Pacific Journal of Cancer Prevention, vol. 15, no. 5, pp. 2323-2328, 2014.
198. M. Tio, J. Andrici, and G. D. Eslick, "Folate intake and the risk of breast cancer: A systematic review andmeta-analysis, " Breast Cancer Research and Treatment, vol. 145, no. 2, pp. 513-524, 2014.
199. J. K. Bassett, L. Baglietto, A. M. Hodge et al., "Dietary intake of B vitamins and methionine and breast cancer risk, " Cancer Causes and Control, vol. 24, no. 8, pp. 1555-1563, 2013.
200. T. A. Sellers, S. R. Alberts, R. A. Vierkant et al., "High-folate diets and breast cancer survival in a prospective cohort study, " Nutrition and Cancer, vol. 44, no. 2, pp. 139-144, 2002.
201. C. Castillo-L, J. A. Tur, and R. Uauy, "Folate and breast cancer risk. A systematic review, " Revista Medica de Chile, vol. 140, no. 2, pp. 251-260, 2012.
202. J. Lin, I. M. Lee, Cook N. R. et al., "Plasma folate, vitamin B-6, vitamin B-12 and risk of breast cancer in women, "The American Journal of Clinical Nutrition, vol. 87, pp. 734-743, 2008.
203. E. Riboli, K. J. Hunt, N. Slimani et al., "European prospective investigation into cancer and nutrition (EPIC): study populations and data collection, " Public Health Nutrition, vol. 5, no. 6, pp. 1113-1124, 2002.
204. G. Rukundo, M. Galukande, P. Ongom, and J. O. Fualal, "Red blood cell folate as a risk factor for breast cancer among patients at a tertiary hospital in Uganda: A case control study, " World Journal of Surgical Oncology, vol. 12, no. 1, article no. 260, 2014.
205. Y.-F. Zhang, W.-W. Shi, H.-F. Gao, L. Zhou, A.-J. Hou, and Y.-H. Zhou, "Folate intake and the risk of breast cancer: A doseresponse meta-analysis of prospective studies, " PLoS ONE, vol. 9, no. 6, Article IDe100044, 2014.
206. S. C. Larsson, L. Bergkvist, and A. Wolk, "Folate intake and risk of breast cancer by estrogen and progesterone receptor status in a Swedish cohort, " Cancer Epidemiology Biomarkers and Prevention, vol. 17, no. 12, pp. 3444-3449, 2008.
207. L. Yu, Y. Tan, and L. Zhu, "Dietary vitamin B2 intake and breast cancer risk: A systematic review and meta-analysis, " Archives of Gynecology and Obstetrics, vol. 295, no. 3, pp. 721-729, 2017.
208. C.-X. Zhang, S. C. Ho, Y.-M. Chen, F.-Y. Lin, J.-H. Fu, and S.-Z. Cheng, "Dietary folate, vitamin B 6, vitamin B 12 and methionine intake and the risk of breast cancer by oestrogen and progesterone receptor status, " British Journal of Nutrition, vol. 106, no. 6, pp. 936-943, 2011.
209. Y.-C. Chou, C.-H. Chu, M.-H. Wu et al., "Dietary intake of vitamin B6 and risk of breast cancer in Taiwanese women, " Journal of Epidemiology, vol. 21, no. 5, pp. 329-336, 2011.
210. U. Ericson, E. Sonestedt, B. Gullberg, H. Olsson, and E. Wirfält, "High folate intake is associated with lower breast cancer incidence in postmenopausal women in the malmö diet and cancer cohort, "The American Journal of Clinical Nutrition, vol. 86, no. 2, pp. 434-443, 2007.
211. M. Lajous, I. Romieu, S. Sabia, M.-C. Boutron-Ruault, and F. Clavel-Chapelon, "Folate, vitamin B12 and postmenopausal breast cancer in a prospective study of French women, " Cancer Causes and Control, vol. 17, no. 9, pp. 1209-1213, 2006.
212. M. J. Shrubsole, F. Jin, Q. Dai et al., "Dietary folate intake and breast cancer risk: results from the shanghai breast cancer study, " Cancer Research, vol. 61, no. 19, pp. 7136-7141, 2001.
213. D. Yang, R. N. Baumgartner, M. L. Slattery et al., "Dietary Intake of Folate, B-Vitamins and Methionine and Breast Cancer Risk amongHispanic andNon-HispanicWhiteWomen, " PLoSONE, vol. 8, no. 2, Article ID e54495, 2013.
214. M. J. Shrubsole, X. O. Shu, H.-L. Li et al., "Dietary B vitamin and methionine intakes and breast cancer risk among Chinese women, " American Journal of Epidemiology, vol. 173, no. 10, pp. 1171-1182, 2011.
215. S. C. Larsson, E. Giovannucci, and A. Wolk, "Folate and risk of breast cancer: A meta-analysis, " Journal of the National Cancer Institute, vol. 99, no. 1, pp. 64-76, 2007.
216. S. M. Zhang, W. C. Willett, J. Selhub et al., "Plasma folate, vitamin B6, vitamin B12, homocysteine and risk of breast cancer, " Journal of the National Cancer Institute, vol. 95, pp. 373-380, 2003.
217. W. Wu, S. Kang, and D. Zhang, "Association of vitamin B 6, vitamin B 12 and methionine with risk of breast cancer: A doseresponse meta-analysis, " British Journal of Cancer, vol. 109, no. 7, pp. 1926-1944, 2013.
218. C. Agnoli, S. Grioni, V. Krogh et al., "Plasma riboflavin and vitamin B-6, but not homocysteine, folate, or vitamin B-12, are inversely associated with breast cancer risk in the european prospective investigation into cancer and nutrition-varese cohort, " Journal of Nutrition, vol. 146, no. 6, pp. 1227-1234, 2016.
219. J. M. He, C. Liping, and L. Dequan, "Association between dietary intake of folate, Vitamin B-6, B-12 & MTHFR, MTR Genotype and breast cancer risk, " Genetics and Molecular Research, vol. 13, no. 84, pp. 8925-8931, 2014.
220. E. Ma, M. Iwasaki, M. Kobayashi et al., "Dietary intake of folate, vitamin B2, vitamin B6, vitamin B12, genetic polymorphism of related enzymes, and risk of breast cancer: A case-control study in Japan, "Nutrition and Cancer, vol. 61, no. 4, pp. 447-456, 2009.
221. Q. Jiang-hua, J. De-chuang, L. Zhen-duo, C. Shu-de, and L. Zhenzhen, "Association ofmethylenetetrahydrofolate reductase and methionine synthase polymorphisms with breast cancer risk and interaction with folate, vitamin B6, and vitamin B12 intakes, " Tumor Biology, vol. 35, no. 12, pp. 11895-11901, 2014.
222. Z. Weiwei, C. Liping, and L. Dequan, "Association between dietary intake of folate, vitamin B6, B12& MTHFR, MTR Genotype and breast cancer risk, " Pakistan Journal of Medical Sciences, vol. 30, no. 1, pp. 106-110, 2014.
223. Y. Liu, L.-S. Zhou, X.-M. Xu, L.-Q. Deng, and Q.-K. Xiao, "Association of dietary intake of folate, vitamin B6 and B12 and MTHFR genotype with breast cancer risk, " Asian Pacific Journal of Cancer Prevention, vol. 14, no. 9, pp. 5189-5192, 2013.
224. E. Ma, M. Iwasaki, I. Junko et al., "Dietary intake of folate, vitamin B6, and vitamin B12, genetic polymorphism of related enzymes, and risk of breast cancer: A case-control study in Brazilian women, " BMC Cancer, vol. 9, article no. 122, 2009.
225. S. Pirouzpanah, F.-A. Taleban, P. Mehdipour, and M. Atri, "Association of folate and other one-carbon related nutrients with hypermethylation status and expression of RARB, BRCA1, and RASSF1A genes in breast cancer patients, " Journal of Molecular Medicine, vol. 93, no. 8, pp. 917-934, 2015.
226. X. Xu, M. D. Gammon, J. G. Wetmur et al., "B-vitamin intake, one-carbon metabolism, and survival in a population-based study of women with breast cancer, " Cancer Epidemiology Biomarkers and Prevention, vol. 17, no. 8, pp. 2109-2116, 2008.
227. J. Wohlrab, N. Bangemann, A. Kleine-Tebbe et al., "Barrier protective use of skin care to prevent chemotherapy-induced cutaneous symptoms and to maintain quality of life in patients with breast cancer, " Breast Cancer: Targets and Therapy, vol. 6, pp. 115-122, 2014.
228. S. Straka, J. L. Lester, R. M. Cole et al., "Incorporation of eicosapentaenioic and docosahexaenoic acids into breast adipose tissue of women at high risk of breast cancer: A randomized clinical trial of dietary fish and n-3 fatty acid capsules, " Molecular Nutrition and Food Research, vol. 59, no. 9, pp. 1780-1790, 2015.
229. C. Pouchieu, V. Chajès, F. Laporte et al., "Prospective associations between plasma saturated, monounsaturated and polyunsaturated fatty acids and overall and breast cancer risk-modulation by antioxidants: A nested case-control study, " PLoS ONE, vol. 9, no. 2, 2014.
230. R. E. Patterson, S. W. Flatt, V. A. Newman et al., "Marine fatty acid intake is associated with breast cancer prognosis, " Journal of Nutrition, vol. 141, no. 2, pp. 201-206, 2011.
231. Y. Cao, L. Hou, and W. Wang, "Dietary total fat and fatty acids intake, serum fatty acids and risk of breast cancer: A metaanalysis of prospective cohort studies, " International Journal of Cancer, vol. 138, no. 8, pp. 1894-1904, 2016.
232. P. M. Witt, J. H. Christensen, E. B. Schmidt et al., "Marine n-3 polyunsaturated fatty acids in adipose tissue and breast cancer risk: A case-cohort study from Denmark, " Cancer Causes and Control, vol. 20, no. 9, pp. 1715-1721, 2009.
233. W. Zhihui, Y. Weihua, W. Zupei, and H. Jinlin, "Fish consumption and risk of breast cancer:meta-analysis of 27 observational studies, " Nutricion Hospitalaria, vol. 33, no. 3, p. 282, 2016.
234. D. Engeset, E. Alsaker, E. Lund et al., "Fish consumption and breast cancer risk. The European Prospective Investigation into Cancer and Nutrition (EPIC), " International Journal of Cancer, vol. 119, no. 1, pp. 175-182, 2006.
235. T. M. Brasky, J. W. Lampe, J. D. Potter, R. E. Patterson, and E. White, "Specialty supplements and breast cancer risk in the VITamins and Lifestyle (VITAL) cohort, " Cancer Epidemiology Biomarkers and Prevention, vol. 19, no. 7, pp. 1696-1708, 2010.
236. J. Kim, S.-Y. Lim, A. Shin et al., "Fatty fish and fish omega-3 fatty acid intakes decrease the breast cancer risk: A case-control study, " BMC Cancer, vol. 9, article no. 216, 2009.
237. L. R. Orr, J. BruceRedmon, M. S. Kurzer, and S. K. Raatz, "Effect of high omega-3 fatty acid diet on markers of breast cancer risk in postmenopausal women, " The FASEB Journal, vol. 23, supplement 558. 2, no. 1, 2009.
238. J. S. Zheng, X. J. Hu, Y. M. Zhao, J. Yang, and D. Li, "ntake of fish and marine n-3 polyunsaturated fatty acids and risk of breast cancer: meta-analysis of data from 21 independent prospective cohort studies, " British Medical Journal, vol. 346, Article ID f3706, 2013.
239. B. Yang, X.-L. Ren, Y.-Q. Fu, J.-L. Gao, and D. Li, "Ratioof n-3/n-6 PUFAs and risk of breast cancer: A meta-analysis of 274135 adult females from 11 independent prospective studies, " BMC Cancer, vol. 14, no. 1, article no. 105, 2014.
240. H. J. Murff, X. Shu, H. Li et al., "Dietary polyunsaturated fatty acids and breast cancer risk in Chinese women: A prospective cohort studyomega-3, " International Journal of Cancer, vol. 128, no. 6, pp. 1434-1441, 2011.
241. N. K. Khankari, P. T. Bradshaw, S. E. Steck et al., "Polyunsaturated fatty acid interactions and breast cancer incidence: A population-based case-control study on Long Island, New York, " Annals of Epidemiology, vol. 25, no. 12, pp. 929-935, 2015.
242. L. D. Yee, J. L. Lester, R. M. Cole et al., "3 fatty acid supplements in women at high risk of breast cancer have dose-dependent effects on breast adipose tissue fatty acid composition, " The American Journal of Clinical Nutrition, vol. 91, no. 5, pp. 1185-1194, 2010.
243. C. J. Fabian, B. F. Kimler, T. A. Phillips et al., "Modulation of breast cancer risk biomarkers by high-dose omega-3 fatty acids: Phase II pilot study in postmenopausal women, " Cancer Prevention Research, vol. 8, no. 10, pp. 922-931, 2015.
244. N. Sandhu, S. E. Schetter, J. Liao et al., "Influence of obesity on breast density reduction by omega-3 fatty acids: Evidence from a randomized clinical trial, " Cancer Prevention Research, vol. 9, no. 4, pp. 275-282, 2016.
245. C. Signori, C. Dubrock, J. P. Richie et al., "Administration of omega-3 fatty acids and Raloxifene to women at high risk of breast cancer: Interim feasibility and biomarkers analysis from a clinical trial, " European Journal of Clinical Nutrition, vol. 66, no. 8, pp. 878-884, 2012.
246. C. Signori, J. P. Richie, B. Prokopczyk et al., "Effect of omega-3 fatty acids alone and in combination with raloxifene on biomarkers of breast cancer risk in postmenopausal healthy womenat high risk, " Journal of ClinicalOncology, vol. 29, e11036, no. 15, 2011.
247. P. Bougnoux, N. Hajjaji, M. N. Ferrasson, B. Giraudeau, C. Couet, and O. Le Floch, "Improving outcome of chemotherapy of metastatic breast cancer by docosahexaenoic acid: A phase II trial, " British Journal of Cancer, vol. 101, no. 12, pp. 1978-1985, 2009.
248. H. L. Hutchins-Wiese, K. Picho, B. A. Watkins et al., "High-Dose eicosapentaenoic acid and docosahexaenoic acid supplementation reduces bone resorption in postmenopausal breast cancer survivors on aromatase inhibitors: A pilot study, " Nutrition and Cancer, vol. 66, no. 1, pp. 68-76, 2014.
249. D. García Giménez, E. García Prado, T. Sáenz Rodríguez, A. Fernández Arche, and R. De La Puerta, "Cytotoxic effect of the pentacyclic oxindole alkaloid mitraphylline isolated from uncaria tomentosa bark on human ewing's sarcoma and breast cancer cell lines, " PlantaMedica, vol. 76, no. 2, pp. 133-136, 2010.
250. Y. Sheng, L. Li, K. Holmgren, and R. W. Pero, "DNA repair enhancement of aqueous extracts of Uncaria tomentosa in a human volunteer study, " Phytomedicine, vol. 8, no. 4, pp. 275-282, 2001.
251. Y. Sheng, R. W. Pero, and H. Wagner, "Treatment of chemotherapy-induced leukopenia in a ratmodel with aqueous extract from Uncaria tomentosa, " Phytomedicine, vol. 7, no. 2, pp. 137-143, 2000.
252. S. Eberlin, L. M. B. dos Santos, and M. L. S. Queiroz, "Uncaria tomentosa extract increases the number of myeloid progenitor cells in the bone marrow of mice infected with Listeria monocytogenes, " International Immunopharmacology, vol. 5, no. 7-8, pp. 1235-1246, 2005.
253. I. Farias, M. do Carmo Aráujo, and E. S. Zimmermann, "Uncaria tomentosa stimulates the proliferation of myeloid progenitor cells, " Journal of Ethnopharmacology, vol. 137, no. 1, pp. 856-863, 2011.
254. Y. Sheng, C. Bryngelsson, and R. W. Pero, "Enhanced DNA repair, immune function and reduced toxicity of C-MED-100(TM), a novel aqueous extract from Uncaria tomentosa, " Journal of Ethnopharmacology, vol. 69, no. 2, pp. 115-126, 2000.
255. L. Allen-Hall, P. Cano, J. T. Arnason, R. Rojas, O. Lock, and R. M. Lafrenie, "Treatment of THP-1 cells with Uncaria tomentosa extracts differentially regulates the expression if IL-1α and TNF-α, " Journal of Ethnopharmacology, vol. 109, no. 2, pp. 312-317, 2007.
256. F. Budán, I. Szabõ, T. Varjas et al., "Mixtures of Uncaria and Tabebuia extracts are potentially chemopreventive in CBA/Ca mice: A long-term experiment, " Phytotherapy Research, vol. 25, no. 4, pp. 493-500, 2011.
257. S. Lamm, Y. Sheng, and R. W. Pero, "Persistent response to pneumococcal vaccine in individuals supplemented with a novelwater soluble extract ofUncaria tomentosa, C-Med-100-, " Phytomedicine, vol. 8, no. 4, pp. 267-274, 2001.
258. S. Alam, D. Katiyar, R. Goel, A. Vats, and A. Mittal, "Role of herbals in cancer management, " The Journal of Phytopharmacology, vol. 2, pp. 46-51, 2013.
259. J. A. Milner, "Garlic: its anticarcinogenic and antitumorigenic properties, " Nutrition Reviews, vol. 54, no. 11, pp. S82-S86, 1996.
260. Y. Liu, P. Zhu, Y. Wang et al., "Antimetastatic therapies of the polysulfide diallyl trisulfide against triple-negative breast cancer (TNBC) via suppressing MMP2/9 by blocking NF-kB and ERK/MAPK signaling pathways, " PLoS ONE, vol. 10, no. 4, Article ID e0123781, 2015.
261. K. Chandra-Kuntal, J. Lee, and S. V. Singh, "Critical role for reactive oxygen species in apoptosis induction and cell migration inhibition by diallyl trisulfide, a cancer chemopreventive component of garlic, " Breast Cancer Research and Treatment, vol. 138, no. 1, pp. 69-79, 2013.
262. A. Malki, M. El-Saadani, and A. S. Sultan, "Garlic constituent diallyl trisulfide induced apoptosis in MCF7 human breast cancer cells, " Cancer biology & therapy, vol. 8, no. 22, pp. 2175-2185, 2009.
263. Y. M. Nkrumah-Elie, J. S. Reuben, A. Hudson et al., "Diallyl trisulfide as an inhibitor of benzo(a)pyrene-induced precancerous carcinogenesis in MCF-10A cells, " Food and Chemical Toxicology, vol. 50, no. 7, pp. 2524-2530, 2012.
264. A. Tsubura, Y.-C. Lai, M. Kuwata, N. Uehara, and K. Yoshizawa, "Anticancer effects of garlic and garlic-derived compounds for breast cancer control, " Anti-Cancer Agents in Medicinal Chemistry, vol. 11, no. 3, pp. 249-253, 2011.
265. H.-K. Na, E.-H. Kim, M.-A. Choi, J.-M. Park, D.-H. Kim, and Y.-J. Surh, "Diallyl trisulfide induces apoptosis in human breast cancer cells through ROS-mediated activation of JNK and AP-1, " Biochemical Pharmacology, vol. 84, no. 10, pp. 1241-1250, 2012.
266. H. Nakagawa, K. Tsuta, K. Kiuchi et al., "Growth inhibitory effects of diallyl disulfide on human breast cancer cell lines, " Carcinogenesis, vol. 22, no. 6, pp. 891-897, 2001.
267. S. Shishodia and B. B. Aggarwal, "Nuclear factor-kappaB activation: A question of life or death, " Journal of Biochemistry and Molecular Biology, vol. 35, no. 1, pp. 28-40, 2002.
268. V. A. Kiesel andS. D. Stan, "Diallyl trisulfide, a chemopreventive agent fromAlliumvegetables, inhibits alpha-secretases in breast cancer cells, " Biochemical and Biophysical Research Communications, vol. 484, no. 4, pp. 833-838, 2017.
269. P. Mason, Dietary Supplements, 3rd edition, 2007, Pharmaceutical Press.
270. L. U. Thompson, P. Robb, M. Serraino, and F. Cheung, "Mammalian Lignan Production From Various Foods, " Nutrition and Cancer, vol. 16, no. 1, pp. 43-52, 1991.
271. H. B. Mabrok, R. Klopfleisch, K. Z. Ghanem, T. Clavel, M. Blaut, and G. Loh, "Lignan transformation by gut bacteria lowers tumor burden in a gnotobiotic rat model of breast cancer, " Carcinogenesis, vol. 33, no. 1, pp. 203-208, 2012.
272. J. K. Mason and L. U. Thompson, "Flaxseed and its lignan and oil components: Can they play a role in reducing the risk of and improving the treatment of breast cancer?" Applied Physiology, Nutrition and Metabolism, vol. 39, no. 6, pp. 663-678, 2014.
273. J. Lee and K. Cho, "Flaxseed sprouts induce apoptosis and inhibit growth in MCF-7 and MDA-MB-231 human breast cancer cells, " In Vitro Cellular and Developmental Biology-Animal, vol. 48, no. 4, pp. 244-250, 2012.
274. C. Theil, V. Briese, D.-U. Richter, U. Jeschke, and K. Friese, "An ethanolic extract of Linum usitatissimum caused cell lethality and inhibition of cell vitality/-proliferation of MCF-7 and BT20 mamma carcinoma cells in vitro, " Archives of Gynecology and Obstetrics, vol. 288, no. 1, pp. 149-153, 2013.
275. A. K. A. Wiggins, S. Kharotia, J. K. Mason, and L. U. Thompson, "Linolenic Acid Reduces Growth of Both Triple Negative and Luminal Breast Cancer Cells in High and Low Estrogen Environments, " Nutrition and Cancer, vol. 67, no. 6, pp. 1001-1009, 2015.
276. A. Sorice, E. Guerriero, M. G. Volpe et al., "Differential response of two human breast cancer cell lines to the phenolic extract from flaxseed oil, " Molecules, vol. 21, no. 3, article no. 319, 2016.
277. J. K. Saggar, J. Chen, P. Corey, and L. U. Thompson, "The effect of secoisolariciresinol diglucoside and flaxseed oil, alone and in combination, onMCF-7 tumor growth and signaling pathways, " Nutrition and Cancer, vol. 62, no. 4, pp. 533-542, 2010.
278. J. S. Truan, J. M. Chen, and L. U. Thompson, "Flaxseed oil reduces the growth of human breast tumours (MCF-7) at high levels of circulating estrogen, " Molecular Nutrition & Food Research, vol. 54, no. 10, pp. 1414-1421, 2010.
279. M. B. Jungeström, L. U. Thompson, and C. Dabrosin, "Flaxseed and its lignans inhibit estradiol-induced growth, angiogenesis, and secretion of vascular endothelial growth factor in human breast cancer xenografts in vivo, " Clinical Cancer Research, vol. 13, no. 3, pp. 1061-1067, 2007.
280. J. Chen, J. K. Saggar, P. Corey, and L. U. Thompson, "Flaxseed cotyledon fraction reduces tumour growth and sensitises tamoxifen treatment of human breast cancer xenograft (MCF-7) in athymic mice, " British Journal of Nutrition, vol. 105, no. 3, pp. 339-347, 2011.
281. J. Chen, J. K. Saggar, P. Corey, and L. U. Thompson, "Flaxseed and pure secoisolariciresinol diglucoside, but not flaxseed hull, reduce human breast tumor growth (MCF-7) in athymic mice, " Journal of Nutrition, vol. 139, no. 11, pp. 2061-2066, 2009.
282. L. Wang, J. Chen, and L. U. Thompson, "The inhibitory effect of flaxseed on the growth and metastasis of estrogen receptor negative human breast cancer xenografts is attributed to both its lignan and oil components, " International Journal of Cancer, vol. 116, no. 5, pp. 793-798, 2005.
283. J. Chen, K. A. Power, J. Mann, A. Cheng, and L. U. Thompson, "Flaxseed alone or in combination with tamoxifen inhibits MCF-7 breast tumor growth in ovariectomized athymic mice with high circulating levels of estrogen, " Experimental Biology and Medicine, vol. 232, no. 8, pp. 1071-1080, 2007.
284. C. Dabrosin, J. Chen, L. Wang, and L. U. Thompson, "Flaxseed inhibits metastasis and decreases extracellular vascular endothelial growth factor in human breast cancer xenografts, " Cancer Letters, vol. 185, no. 1, pp. 31-37, 2002.
285. L. U. Thompson, J. M. Chen, T. Li, K. Strasser-Weippl, and P. E. Goss, "Dietary flaxseed alters tumor biological markers in postmenopausal breast cancer, " Clinical Cancer Research, vol. 11, no. 10, pp. 3828-3835, 2005.
286. K. Buck, A. Vrieling, A. K. Zaineddin et al., "Serum enterolactone and prognosis of postmenopausal breast cancer, " Journal of Clinical Oncology, vol. 29, no. 28, pp. 3730-3738, 2011.
287. E. Guerriero, A. Sorice, F. Capone et al., "Combining doxorubicin with a phenolic extract fromflaxseed oil: evaluation of the effect on two breast cancer cell lines, " International Journal of Oncology, vol. 50, no. 2, pp. 468-476, 2017.
288. J. K. Mason, M.-H. Fu, J. Chen, Z. Yu, and L. U. Thompson, "Dietary flaxseed-trastuzumab interactive effects on the growth of HER2-overexpressing human breast tumors (BT-474), " Nutrition and Cancer, vol. 65, no. 3, pp. 451-459, 2013.
289. J. Mason, "Interactive effects of flaxseed oil and trastuzumab on the groeth of breast tumours overexpressing HER2, " in Nutritional Sciences, p. 86, Toronto, Toronto, Ontario, Canada, 2010.
290. J. Chen, J. K. Saggar, W. E. Ward, and L. U. Thompson, "Effectsof flaxseed lignan and oil on bone health of breast-tumor-bearing mice treated with or without tamoxifen, " Journal of Toxicology and Environmental Health-Part A: Current Issues, vol. 74, no. 12, pp. 757-768, 2011.
291. A. Krup, L. H. Prakash, and A. Harini, "Pharmacological activities of turmeric (Curcuma longa linn): A reviw, " Journal of Homeopathy & Ayurvedic Medicine, vol. 2, pp. 133-136, 2013.
292. D. Liu and Z. Chen, "The effect of curcumin on breast cancer cells, " Journal of Breast Cancer, vol. 16, no. 2, pp. 133-137, 2013.
293. A. B. Kunnumakkara, P. Anand, and B. B. Aggarwal, "Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins, " Cancer Letters, vol. 269, no. 2, pp. 199-225, 2008.
294. N. Cine, P. Limtrakul, D. Sunnetci, B. Nagy, and H. Savli, "Effects of curcumin on global gene expression profiles in the highly invasive human breast carcinoma cell lineMDA-MB 231: A gene network-based microarray analysis, " Experimental and Therapeutic Medicine, vol. 5, no. 1, pp. 23-27, 2013.
295. M. Jiang, O. Huang, X. Zhang et al., "Curcumin induces cell death and restores tamoxifen sensitivity in the antiestrogenresistant breast cancer cell lines MCF-7/LCC2 and MCF-7/LCC9, " Molecules, vol. 18, no. 1, pp. 701-720, 2013.
296. Y. Zhan, Y. Chen, R. Liu, H. Zhang, and Y. Zhang, "Potentiation of paclitaxel activity by curcumin in human breast cancer cell by modulating apoptosis and inhibiting EGFR signaling, " Archives of Pharmacal Research, vol. 37, no. 8, pp. 1086-1095, 2014.
297. H. J. Kang, S. H. Lee, J. E. Price, and L. S. Kim, "Curcumin suppresses the paclitaxel-induced nuclear factor-kappaB in breast cancer cells and potentiates the growth inhibitory effect of paclitaxel in a breast cancer nude mice model, " The Breast Journal, vol. 15, no. 3, pp. 223-229, 2009.
298. E. T. Quispe-Soto and G. M. Calaf, "Effect of curcumin and paclitaxel on breast carcinogenesis, " International Journal of Oncology, vol. 49, no. 6, pp. 2569-2577, 2016.
299. Z. F. Zhong, W. Tan, K. Tian, H. Yu, W. Qiang, and Y. Wang, "Combined effects of furanodiene and doxorubicin on the migration and invasion of MDA-MB-231 breast cancer cells in vitro, " Oncology Reports, vol. 37, no. 4, pp. 2016-2024, 2017.
300. L. C. Ferreira, A. S. Arbab, B. V. Jardim-Perassi et al., "Effect of curcumin on pro-angiogenic factors in the xenograft model of breast cancer, " Anti-Cancer Agents in Medicinal Chemistry, vol. 15, no. 10, pp. 1285-1296, 2015.
301. T.-L. Chiu and C.-C. Su, "Curcumin inhibits proliferation and migration by increasing the Bax to Bcl-2 ratio and decreasing NF-kappaBp65 expression in breast cancerMDA-MB-231 cells, " International Journal of Molecular Medicine, vol. 23, no. 4, pp. 469-475, 2009.
302. H. Zong, F. Wang, Q.-X. Fan, and L.-X. Wang, "Curcumin inhibits metastatic progression of breast cancer cell through suppression of urokinase-type plasminogen activator by NFkappa B signaling pathways, "Molecular Biology Reports, vol. 39, no. 4, pp. 4803-4808, 2012.
303. S. Bimonte, A. Barbieri, G. Palma et al., "Dissecting the role of curcumin in tumour growth and angiogenesis in mouse model of human breast cancer, " BioMed Research International, vol. 2015, Article ID 878134, 2015.
304. H.-W. Lai, S.-Y. Chien, S.-J. Kuo et al., "The potential utility of curcumin in the treatment of HER-2-overexpressed breast cancer: An in vitro and in vivo comparison studywith herceptin, " Evidence-Based Complementary and Alternative Medicine, vol. 2012, Article ID486568, 12 pages, 2012.
305. H. Fan, Y. Liang, B. Jiang et al., "Curcumin inhibits intracellular fatty acid synthase and induces apoptosis in human breast cancer MDA-MB-231 cells, " Oncology Reports, vol. 35, no. 5, pp. 2651-2656, 2016.
306. C. E. Carroll, M. R. Ellersieck, and S. M. Hyder, "Curcumin inhibits MPA-induced secretion of VEGF from T47-D human breast cancer cells, " Menopause, vol. 15, no. 3, pp. 570-574, 2008.
307. G. Chakraborty, S. Jain, S. Kale et al., "Curcumin suppresses breast tumour angiogenesis by abrogating osteopontin-induced VEGF expression, "MolecularMedicine Reports, vol. 1, no. 5, pp. 641-646, 2008.
308. Y. H. Soung and J. Chung, "Curcumin inhibition of the functional interaction between integrin alpha6beta4 and the epidermal growth factor receptor, "Molecular CancerTherapeutics, vol. 10, no. 5, pp. 883-891, 2011.
309. M. M. Yallapu, M. Jaggi, and S. C. Chauhan, "Curcumin nanoformulations: A future nanomedicine for cancer, " Drug Discovery Today, vol. 17, no. 1-2, pp. 71-80, 2012.
310. M. Z. Ahmad, S. A. Alkahtani, S. Akhter et al., "Progress in nanotechnology-based drug carrier in designing of curcumin nanomedicines for cancer therapy: Current state-of-the-art, " Journal of Drug Targeting, vol. 24, no. 4, pp. 273-293, 2016.
311. M. M. Yallapu, S. F. Othman, E. T. Curtis et al., "Curcuminloaded magnetic nanoparticles for breast cancer therapeutics and imaging applications, " International Journal of Nanomedicine, vol. 7, pp. 1761-1779, 2012.
312. P. Verderio, P. Bonetti, M. Colombo, L. Pandolfi, and D. Prosperi, "Intracellular drug release from curcumin-loaded PLGA nanoparticles induces G2/M block in breast cancer cells, " Biomacromolecules, vol. 14, no. 3, pp. 672-682, 2013.
313. Y. Cai, Z. Sun, X. Fang et al., "Synthesis, characterization and anti-cancer activity of Pluronic F68-curcumin conjugate micelles, " Drug Delivery, vol. 23, no. 7, pp. 2587-2595, 2016.
314. S. Somasundaram, Edmund N. A., Moore D. T., Small G. W., Shi Y. Y., and Orlowski R. Z., "Dietary curcumin inhibits chemotherapy-induced apoptosis in models of human breast cancer, " Cancer Research, vol. 62, no. 13, pp. 3868-3875, 2002.
315. N. T. Zaveri, "Green tea and its polyphenolic catechins: medicinal uses in cancer and noncancer applications, " Life Sciences, vol. 78, no. 18, pp. 2073-2080, 2006.
316. R. L. Thangapazham, N. Passi, and R. K. Maheshwari, "Green tea polyphenol and epigallocatechin gallate induce apoptosis and inhibit invasion in human breast cancer cells, " Cancer Biology andTherapy, vol. 6, no. 12, pp. 1938-1943, 2007.
317. R. L. Thangapazham, A. K. Singh, A. Sharma, J. Warren, J. P. Gaddipati, and R. K. Maheshwari, "Green tea polyphenols and its constituent epigallocatechin gallate inhibits proliferation of human breast cancer cells in vitro and in vivo, " Cancer Letters, vol. 245, no. 1-2, pp. 232-241, 2007.
318. Z. Wang, N. Wang, S. Han et al., "Dietary Compound Isoliquiritigenin Inhibits Breast Cancer Neoangiogenesis via VEGF/ VEGFR-2 Signaling Pathway, " PLoS ONE, vol. 8, no. 7, Article ID e68566, 2013.
319. A. H. Wu and L. M. Butler, "Green tea and breast cancer, " Molecular Nutrition and Food Research, vol. 55, no. 6, pp. 921-930, 2011.
320. E. Lecumberri, Y. M. Dupertuis, R. Miralbell, and C. Pichard, "Green tea polyphenol epigallocatechin-3-gallate (EGCG) as adjuvant in cancer therapy, " Clinical Nutrition, vol. 32, no. 6, pp. 894-903, 2013.
321. F. Farabegoli, A. Papi, G. Bartolini, R. Ostan, and M. Orlandi, "(-)-epigallocatechin-3-gallate downregulates Pg-P and BCRP in a tamoxifen resistantMCF-7 cell line, " Phytomedicine, vol. 17, no. 5, pp. 356-362, 2010.
322. T. Luo, J. Wang, Y. Yin et al., "(-)-Epigallocatechin gallate sensitizes breast cancer cells to paclitaxel in a murine model of breast carcinoma, " Breast Cancer Research, vol. 12, no. 1, article R8, 2010.
323. Y. Zhou, J. Tang, Y. Du, J. Ding, and J.-Y. Liu, "The green tea polyphenol EGCG potentiates the antiproliferative activity of sunitinib in human cancer cells, " Tumor Biology, vol. 37, no. 7, pp. 8555-8566, 2016.
324. S.-H. Tu, C.-Y. Ku, C.-T. Ho et al., "Tea polyphenol (-)-epigallocatechin-3-gallate inhibits nicotine-and estrogeninduced α9-nicotinic acetylcholine receptor upregulation in human breast cancer cells, " Molecular Nutrition & Food Research, vol. 55, no. 3, pp. 455-466, 2011.
325. Y. Li, Y.-Y. Yuan, S. M. Meeran, and T. O. Tollefsbol, "Synergistic epigenetic reactivation of estrogen receptor-α (ERα) by combined green tea polyphenol and histone deacetylase inhibitor in ERα-negative breast cancer cells, " Molecular Cancer, vol. 9, article no. 274, 2010.
326. C. I. Coleman, J. H. Hebert, and P. Reddy, "The effects of Panax ginseng on quality of life, " Journal of Clinical Pharmacy and Therapeutics, vol. 28, no. 1, pp. 5-15, 2003.
327. E. Ernst, "Prescribing herbal medications appropriately, " The Journal of Family Practice, vol. 53, no. 12, pp. 985-988, 2004.
328. J.-M. Lü, Q. Yao, and C. Chen, "Ginseng compounds: An update on their molecular mechanisms and medical applications, " Current Vascular Pharmacology, vol. 7, no. 3, pp. 293-302, 2009.
329. M. Blumenthal, "Herb sales down 15 percent in mainstream market, " HerbalGram, vol. 51, p. 69, 2001.
330. D. L. Barton, H. Liu, S. R. Dakhil et al., "Wisconsin Ginseng (Panax quinquefolius) to improve cancer-related fatigue: A randomized, double-blind trial, N07C2, " Journal of the National Cancer Institute, vol. 105, no. 16, pp. 1230-1238, 2013.
331. J.-N. Lai, C.-T. Wu, and J.-D. Wang, "Prescription pattern of Chinese herbal products for breast cancer in Taiwan: A population-based study, " Evidence-Based Complementary and AlternativeMedicine, vol. 2012, Article ID 891893, 7 pages, 2012.
332. J.-H. Kang, K.-H. Song, J.-K. Woo et al., "Ginsenoside Rp1 from Panax ginseng exhibits anti-cancer activity by down-regulation of the IGF-1R/Akt pathway in breast cancer cells, " Plant Foods for Human Nutrition, vol. 66, no. 3, pp. 298-305, 2011.
333. J. H. Kwak, J. Y. Park, D. Lee et al., "Inhibitory effects of ginseng sapogenins on the proliferation of triple negative breast cancer MDA-MB-231 cells, " Bioorganic and Medicinal Chemistry Letters, vol. 24, no. 23, pp. 5409-5412, 2014.
334. A. S. Wong, C. M. Che, and K. W. Leung, "Recent advances in ginseng as cancer therapeutics: A functional and mechanistic overview, " Natural Product Reports, vol. 32, no. 2, pp. 256-272, 2015.
335. B. Kim, D. Kim, J. Park, Y. Surh, and H. Na, "Ginsenoside Rg3 inhibits constitutive activation of NF-kappaB signaling in human breast cancer (MDA-MB-231) cells: ERK and Akt as potential upstream targets, " Journal of Cancer Prevention, vol. 19, no. 1, pp. 23-30, 2014.
336. B. M. Kim, D. Kim, J. Park, H. Na, and Y. Surh, "Ginsenoside Rg3 Induces apoptosis of human breast cancer (MDA-MB-231) cells, " Journal of Cancer Prevention, vol. 18, no. 2, pp. 177-185, 2013.
337. M. Miao, Q. Liu, and Y. R. Liu, "Chemo-sensitivity enhancing effects of Shengai injection on various chemotherapeutic drugs, " Chinese Traditional andHerbalDrugs, vol. 44, pp. 875-876, 2013.
338. N.-H. Lee and C.-G. Son, "Systematic Review of Randomized Controlled Trials Evaluating the Efficacy and Safety ofGinseng, " JAMS Journal of Acupuncture and Meridian Studies, vol. 4, no. 2, pp. 85-97, 2011.
339. J. T. Coon and E. Ernst, "Panax ginseng: A systematic review of adverse effects and drug interactions, " Drug Safety, vol. 25, no. 5, pp. 323-344, 2002.
340. R. Baber, M. Hickey, and M. Kwik, "Therapy for menopausal symptoms during and after treatment for breast cancer: Safety considerations, " Drug Safety, vol. 28, no. 12, pp. 1085-1100, 2005.
341. H. H. Henneicke-von Zepelin, "60 years of Cimicifuga racemosa medicinal products: Clinical research milestones, current study findings and current development, " Wiener Medizinische Wochenschrift, vol. 167, no. 7-8, pp. 147-159, 2017.
342. S. Rockwell, Y. Liu, and S. A. Higgins, "Alteration of the effects of cancer therapy agents on breast cancer cells by the herbal medicine black cohosh, " Breast Cancer Research and Treatment, vol. 90, no. 3, pp. 233-239, 2005.
343. H.-Y. Sun, B.-B. Liu, J.-Y. Hu et al., "Novel cycloartane triterpenoid from Cimicifuga foetida (Sheng ma) induces mitochondrial apoptosis via inhibiting Raf/MEK/ERK pathway and Akt phosphorylation in human breast carcinoma MCF-7 cells, " Chinese Medicine (United Kingdom), vol. 11, no. 1, article no. 1, 2016.
344. Y. Kong, F. Li, Y. Nian et al., "KHF16 is a leading structure from Cimicifuga foetida that suppresses breast cancer partially by inhibiting theNF-kB signaling pathway, "Theranostics, vol. 6, no. 6, pp. 875-886, 2016.
345. G. G.-L. Yue, S. Xie, J. K.-M. Lee et al., "New potential beneficial effects of actein, a triterpene glycoside isolated fromCimicifuga species, in breast cancer treatment, " Scientific Reports, vol. 6, Article ID 35263, 2016.
346. L. S. Einbond, J. Mighty, S. Redenti, and H.-A. Wu, "Actein induces calcium release in human breast cancer cells, " Fitoterapia, vol. 91, pp. 28-38, 2013.
347. U. Weissenstein, M. Kunz, K. Urech, U. Regueiro, and S. Baumgartner, "Interaction of a standardized mistletoe (Viscum album) preparation with antitumor effects of Trastuzumab in vitro, " BMC Complementary and Alternative Medicine, vol. 16, no. 1, article no. 271, 2016.
348. V. L. Davis, M. J. Jayo, A. Ho et al., "Black cohosh increases metastatic mammary cancer in transgenic mice expressing cerbB2, " Cancer Research, vol. 68, no. 20, pp. 8377-8383, 2008.
349. H. Maroof, Z. M. Hassan, A. M. Mobarez, and M. A. Mohamadabadi, "Lactobacillus acidophilus could modulate the immune response against breast cancer in murine model, " Journal of Clinical Immunology, vol. 32, no. 6, pp. 1353-1359, 2012.
350. D. Seidlová-Wuttke, O. Hesse, H. Jarry et al., "Evidence for selective estrogen receptormodulator activity in a black cohosh (Cimicifuga racemosa) extract: Comparison with estradiol-17β, " European Journal of Endocrinology, vol. 149, no. 4, pp. 351-362, 2003.
351. W. Wuttke, C. Gorkow, and D. Seidlová-Wuttke, "Effects of black cohosh (Cimicifuga racemosa) on bone turnover, vaginal mucosa, and various blood parameters in postmenopausal women: A double-blind, placebo-controlled, and conjugated estrogens-controlled study, " Menopause, vol. 13, no. 2, pp. 185-196, 2006.
352. W. Wuttke, D. Seidlová-Wuttke, and C. Gorkow, "The Cimicifuga preparation BNO 1055 vs. conjugated estrogens in a double-blind placebo-controlled study: Effects on menopause symptoms and bone markers, " Maturitas, vol. 44, pp. S67-S77, 2003.
353. R. D. Koos, "Minireview: putting physiology back into estrogens' mechanism of action, " Endocrinology, vol. 152, no. 12, pp. 4481-4488, 2011.
354. B. A. Pockaj, J. G. Gallagher, C. L. Loprinzi et al., "Phase III double-blind, randomized, placebo-controlled crossover trial of black cohosh in the management of hot flashes: NCCTG trial N01CC, " Journal of Clinical Oncology, vol. 24, no. 18, pp. 2836-2841, 2006.
355. B. A. Pockaj, C. L. Loprinzi, J. A. Sloan et al., "Pilot evaluation of black cohosh for the treatment of hot flashes in women, " Cancer Investigation, vol. 22, no. 4, pp. 515-521, 2004.
356. T. Nißlein and J. Freudenstein, "Coadministration of the aromatase inhibitor formestane and an isopropanolic extract of black cohosh in a rat model of chemically induced mammary carcinoma, " Planta Medica, vol. 73, no. 4, pp. 318-322, 2007.
357. B. J. Gurley, S. F. Gardner, M. A. Hubbard et al., "In vivo effects of goldenseal, kava kava, black cohosh, and valerian on human cytochrome P450 1A2, 2D6, 2E1, and 3A4/5 phenotypes, " Clinical Pharmacology andTherapeutics, vol. 77, no. 5, pp. 415-426, 2005.
358. B. J. Gurley, A. Swain, M. A. Hubbard et al., "Clinical assessment of CYP2D6-mediated herb-drug interactions in humans: Effects of milk thistle, black cohosh, goldenseal, kava kava, St. John's wort, and Echinacea, " Molecular Nutrition and Food Research, vol. 52, no. 7, pp. 755-763, 2008.
359. S. Belisle, J. Blake, R. Basson et al., "Canadian Consensus Conference on menopause, 2006 update, " Journal of Obstetrics and Gynaecology Canada, vol. 28, 1, no. 2, pp. S7-S94, 2006.
360. R. Walji, H. Boon, E. Guns, D. Oneschuk, and J. Younus, "Black cohosh (Cimicifuga racemosa [L. ]Nutt.): Safety and efficacy for cancer patients, " Supportive Care in Cancer, vol. 15, no. 8, pp. 913-921, 2007.
361. J. Freudenstein, C. Dasenbrock, and T. Nisslein, "Lack of promotion of estrogen-dependent mammary gland tumours in vivo by an isopropanolic Cimicifuga racemosa extract, " Cancer Research, vol. 62, no. 12, pp. 3448-3452, 2002.
362. R. Teschke, "Black cohosh and suspected hepatotoxicity: inconsistencies, confounding variables, and prospective use of a diagnostic causality algorithm. A critical review, " Menopause, vol. 17, no. 2, pp. 426-440, 2010.
363. A. Büssing, "Biological and pharmacological properties of Viscum album L, " in Mistletoe. The Genus Viscum, Harwood Academic Publishers, Amsterdam, The Netherlands, 2000.
364. T. Hajto, K. Hostanska, J. Fischer, and R. Saller, "Immunomodulatory effects of Viscum album agglutinin-I on natural immunity, " Anti-Cancer Drugs, vol. 8, no. 1, pp. S43-S46, 1997.
365. I. F. Pryme, S. Bardocz, A. Pusztai, and S. W. B. Ewen, "Suppression of growth of tumour cell lines in vitro and tumours in vivo by mistletoe lectins, " Histology and Histopathology, vol. 21, no. 3, pp. 285-299, 2006.
366. M. Harmsma, M. Ummelen, W. Dignef, K. J. Tusenius, and F. C. S. Ramaekers, "Effects of mistletoe (Viscum album L.) extracts Iscador on cell cycle and survival of tumour cells, " Arzneimittelforschung, vol. 56, no. 6A, pp. 474-482, 2006.
367. F. C. S. Ramaekers, M. Harmsma, K. J. Tusenius, B. Schutte, M. Werner, and M. Ramos, "Mistletoe extracts (Viscum album L.) Iscador interact with the cell cycle machinery and target survival mechanisms in cancer cells, " Medicina, vol. 67, no. 2, pp. 79-84, 2007.
368. N. E. Gardin, "Immunological response to mistletoe (Viscum album L.) in cancer patients: A four-case series, " Phytotherapy Research, vol. 23, no. 3, pp. 407-411, 2009.
369. G. S. Son, W. S. Ryu, H. Y. Kim, S. U. Woo, K. H. Park, and J. W. Bae, "Immunologic response to mistletoe extract (Viscum albumL.) after conventional treatment in patientswith operable breast cancer, " Journal of Breast Cancer, vol. 13, no. 1, pp. 14-18, 2010.
370. G. Kelter, J. M. Schierholz, I. U. Fischer, and H. H. Fiebig, "Cytotoxic activity and absence of tumour growth stimulation of standardized mistletoe extracts in human tumour models in vitro, " Anticancer Research, vol. 1A, pp. 223-233, 2007.
371. U. Weissenstein, M. Kunz, K. Urech, and S. Baumgartner, "Interaction of standardized mistletoe (Viscum album) extracts with chemotherapeutic drugs regarding cytostatic and cytotoxic effects in vitro, " BMC Complementary and AlternativeMedicine, vol. 14, article no. 6, 2014.
372. C.-E. Hong, A.-K. Park, and S.-Y. Lyu, "Synergistic anticancer effects of lectin and doxorubicin in breast cancer cells, " Molecular and Cellular Biochemistry, vol. 394, no. 1-2, pp. 225-235, 2014.
373. J. Beuth, H. L. Ko, H. Schneider et al., "Intratumoural application of standardized mistletoe extracts down regulates tumour weight via decreased cell proliferation, increased apoptosis and necrosis in a murine model, " Anticancer Research, vol. 26, no. 6B, pp. 4451-4456, 2006.
374. L. S. Guo, H. X. Li, C. Y. Li et al., "Synergistic antitumour activity of vitamin D3 combined with metformin in human breast carcinoma MDA-MB-231 cells involves m-TOR related signaling pathways, " Pharmazie, vol. 70, no. 2, pp. 117-122, 2015.
375. M. Thill, K. Reichert, A. Woeste et al., "Combined treatment of breast cancer cell lines with vitamin D and COX-2 inhibitors, " Anticancer Research, vol. 35, no. 2, pp. 1189-1195, 2015.
376. M. C. Kahya, M. Naziro?glu, and B. ç i?g, "Selenium reduces mobile phone (900 MHz)-induced oxidative stress, mitochondrial function, and apoptosis in breast cancer cells, " Biological Trace Element Research, vol. 160, no. 2, pp. 285-293, 2014.
377. C. L. Rock, C. Doyle, W. Demark-Wahnefried et al., "Nutrition and physical activity guidelines for cancer survivors, " CA: A Cancer Journal for Clinicians, vol. 62, no. 4, pp. 243-274, 2012.
378. W. C. R. F. A. A. I. f. C. R. WCRF, Cancer Survivors, 2015, http:// www. dietandcancerreport. org/cancer prevention recommendations/ recommendation cancer survivors. php.
379. H. Greenlee, M. L. Kwan, I. J. Ergas et al., "Changes in vitamin and mineral supplement use after breast cancer diagnosis in the Pathways Study: A prospective cohort study, " BMC Cancer, vol. 14, no. 1, article no. 382, 2014.
380. J. Saquib, B. A. Parker, L. Natarajan et al., "Prognosis following the use of complementary and alternative medicine in women diagnosed with breast cancer, " Complementary Therapies in Medicine, vol. 20, no. 5, pp. 283-290, 2012.
381. S. Nechuta, W. Lu, Z. Chen et al., "Vitamin supplement use during breast cancer treatment and survival: A prospective cohort study, " Cancer Epidemiology Biomarkers & Prevention, vol. 20, no. 2, pp. 262-271, 2011.
382. G. R. Zirpoli, P. M. Brennan, C.-C. Hong et al., "Supplement use during an intergroup clinical trial for breast cancer (S0221), " Breast Cancer Research and Treatment, vol. 137, no. 3, pp. 903-913, 2013.
383. M. Harvie, "Nutritional supplements and cancer: potential benefits and proven harms, " American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting, pp. e478-e486, 2014.
384. L. H. Kushi, C. Doyle, M. McCullough et al., "American Cancer Society guidelines on nutrition and physical activity for cancer prevention: reducing the Risk of Cancer with Healthy Food Choices andPhysicalActivity, " CACancer Journal for Clinicians, vol. 62, no. 1, pp. 30-67, 2012.
385. Cancer ResearchUK, TheSafety ofVitamins andDietary Supplements, 2015, http://www. cancerresearchuk. org/about-cancer/ cancers-in-general/treatment/complementary-alternative/about/ harm/the-safety-of-vitamins-and-diet-supplements.
386. B. D. Lawenda and J. B. Blumberg, "Should supplemental antioxidant administration be avoided during chemotherapy and radiation therapy?" Journal of the National Cancer Institute, vol. 100, no. 11, pp. 773-783, 2008.
387. G. M. D'Andrea, "Use of antioxidants during chemotherapy and radiotherapy should be avoided, " A Cancer Journal for Clinicians, vol. 55, no. 5, pp. 319-321, 2005.
388. C. Walker, "Antioxidant supplements do not improve mortality andmay cause harm, " American Family Physician, vol. 78, no. 9, pp. 1079-1080, 2008.
389. G. Bjelakovic, D. Nikolova, L. L. Gluud, R. G. Simonetti, and C. Gluud, "Antioxidant supplements for prevention ofmortality in healthy participants and patients with various diseases, " Cochrane Database of Systematic Reviews, vol. 14, no. 3, Article ID CD007176, 2012.
390. N. Samuels, E. Schiff, and E. Ben-Arye, "Non-herbal nutritional supplements for symptom relief in adjuvant breast cancer: Creating a doctor-patient dialogue, " BMJ Supportive and Palliative Care, vol. 4, no. 3, Article IDArticle e1, 2014.
391. C. Dennehy and C. Tsourounis, "A review of select vitamins and minerals used by postmenopausal women, " Maturitas, vol. 66, no. 4, pp. 370-380, 2010.
392. E. Doldo, G. Costanza, S. Agostinelli et al., "Vitamin A, cancer treatment and prevention: The new role of cellular retinol binding proteins, " BioMed Research International, vol. 2015, Article ID 624627, 2015.
393. J. Lin, N. R. Cook, C. Albert et al., "Vitamins C and E and beta carotene supplementation and cancer risk: A randomized controlled trial, " Journal of theNational Cancer Institute, vol. 101, no. 1, pp. 14-23, 2009.
394. Q. Chen, M. G. Espey, M. C. Krishna et al., "Pharamacologic ascorbic acid concentrations selectively kill cancer cells: Action as a pro-drug to deliver hydrogen peroxide to tissuse, " Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 38, pp. 13604-13609, 2005.
395. M. F. Ullah, H. Y. Khan, H. Zubair, U. Shamim, and S. M. Hadi, "The antioxidant ascorbic acidmobilizes nuclear copper leading to a prooxidant breakage of cellular DNA: implications for chemotherapeutic action against cancer, " Cancer Chemotherapy and Pharmacology, vol. 67, no. 1, pp. 103-110, 2011.
396. J. K. Willcox, S. L. Ash, and G. L. Catignani, "Antioxidants and prevention of chronic disease, " Critical Reviews in Food Science and Nutrition, vol. 44, no. 4, pp. 275-295, 2004.
397. J. Hübner and V. Hanf, "Commonly used methods of complementary medicine in the treatment of breast cancer, " Breast Care, vol. 8, no. 5, pp. 341-347, 2013.
398. A. J. McEligot, J. Largent, A. Ziogas, D. Peel, and H. Anton-Culver, "Dietary fat, fiber, vegetable, and micronutrients are associated with overall survival in postmenopausal women diagnosed with breast cancer, " Nutrition and Cancer, vol. 55, no. 2, pp. 132-140, 2006.
399. C. Jacobs, B. Hutton, T. Ng, R. Shorr, and M. Clemons, "Is there a role for oral or intravenous ascorbate (Vitamin C) in treating patients with cancer? A systematic review, " Oncologist, vol. 20, no. 2, pp. 210-223, 2015.
400. T. Subramani, S. K. Yeap, W. Y. Ho et al., "Vitamin C suppresses cell death in MCF-7 human breast cancer cells induced by tamoxifen, " Journal of Cellular and Molecular Medicine, vol. 18, no. 2, pp. 305-313, 2014.
401. G. Perrone, T. Hideshima, H. Ikeda et al., "Ascorbic acid inhibits antitumor activity of bortezomib in vivo, " Leukemia, vol. 23, no. 9, pp. 1679-1686, 2009.
402. S. J. Padayatty, H. Sun, Y. Wang et al., "Vitamin C Pharmacokinetics: Implications for Oral and Intravenous Use, " Annals of Internal Medicine, vol. 140, no. 7, pp. 533-I61, 2004.
403. H. Greenlee, D. L. Hershman, and J. S. Jacobson, "Use of antioxidant supplements during breast cancer treatment: A comprehensive review, " Breast Cancer Research and Treatment, vol. 115, no. 3, pp. 437-452, 2009.
404. L. J. Hoffer, M. Levine, S. Assouline et al., "Phase I clinical trial of i. v. Ascorbic acid in advanced malignancy, " Annals of Oncology, vol. 19, no. 11, pp. 1969-1974, 2008.
405. S. Swami, A. V. Krishnan, J. Y. Wang et al., "Dietary vitamin D 3and 1, 25-dihydroxyvitamin D 3 (calcitriol) exhibit equivalent anticancer activity in mouse xenograft models of breast and prostate cancer, " Endocrinology, vol. 153, no. 6, pp. 2576-2587, 2012.
406. J. Cha, M. W. Roomi, V. Ivanov, T. Kalinovsky, A. Niedzwiecki, and M. Rath, "Ascorbate supplementation inhibits growth and metastasisof B16FO melanoma and 4T1 breast cancer cellsin vitamin C-deficient mice, " International Journal of Oncology, vol. 42, no. 1, pp. 55-64, 2013.
407. T. E. Ichim, B. Minev, T. Braciak et al., "Intravenous ascorbic acid to prevent and treat cancer-associated sepsis?" Journal of Translational Medicine, vol. 9, article no. 25, 2011.
408. G. Wang, T. Yin, and Y. Wang, "In vitro and in vivo assessment of high-dose vitamin C against murine tumors, " Experimental andTherapeutic Medicine, vol. 12, no. 5, pp. 3058-3062, 2016.
409. E. Lonn, J. Bosch, S. Yusuf et al., "Effects of long-term vitamin E supplementation on cardiovascular events and cancer: A randomized controlled trial, " The Journal of the American Medical Association, vol. 293, no. 11, pp. 1338-1347, 2005.
410. K.-W. Tam, C.-T. Ho, W.-J. Lee et al., "Alteration of α-tocopherol-associated protein (TAP) expression in human breast epithelial cells during breast cancer development, " Food Chemistry, vol. 138, no. 2-3, pp. 1015-1021, 2013.
411. J.-H. Lee, B. Kim, W. J. Jin et al., "Trolox inhibits osteolytic bone metastasis of breast cancer through both PGE2-dependent and independent mechanisms, " Biochemical Pharmacology, vol. 91, no. 1, pp. 51-60, 2014.
412. J. Walston, Q. Xue, R. D. Semba et al., "Serum antioxidants, inflammation, and total mortality in older women, " American Journal of Epidemiology, vol. 163, no. 1, pp. 18-26, 2006.
413. J. Bleys, A. Navas-Acien, M. Laclaustra et al., "Serum selenium and peripheral arterial disease: Results from the national health and nutrition examination survey, 2003-2004, "American Journal of Epidemiology, vol. 169, no. 8, pp. 996-1003, 2009.
414. J. Beuth, "Evidence-based complementary oncology: innovative approaches to optimise standar therapy strategies, " Anticancer Research, vol. 30, no. 5, pp. 1767-1772, 2010.
415. G. Dennert, M. Zwahlen, M. Brinkman, M. Vinceti, M. P. A. Zeegers, and M. Horneber, "Selenium for preventing cancer, " Cochrane Database of Systematic Reviews, vol. 5, Article ID CD005195, 2011.
416. J. Beuth, "Evidence-based complementary medicine in breast cancer therapy, " Breast Care, vol. 4, no. 1, pp. 8-12, 2009.
417. E.-H. Lee, S.-K. Myung, Y.-J. Jeon et al., "Effects of selenium supplements on cancer prevention: Meta-analysis of randomized controlled trials, " Nutrition and Cancer, vol. 63, no. 8, pp. 1185-1195, 2011.
418. X. Cai, C. Wang, W. Yu et al., "Selenium Exposure and Cancer Risk: An Updated Meta-analysis and Meta-regression, " Scientific Reports, vol. 6, Article ID 19213, 2016.
419. U. Gröber, "Antioxidants and other micronutrients in complementary oncology, " Breast Care, vol. 4, no. 1, pp. 13-20, 2009.
420. M. L. Adeoti, A. S. Oguntola, E. O. Akanni, O. S. Agodirin, and G. M. Oyeyemi, "Trace elements; Copper, zinc and selenium, in breast cancer afflicted female patients in LAUTECH Osogbo, Nigeria, " Indian Journal of Cancer, vol. 52, no. 1, pp. 106-109, 2015.
421. R. Muecke, L. Schomburg, and M. Glatzel, "Multicenter, phase III trial comparing selenium supplementation with observation in gynecologic radiation oncology, " International Journal of Radiation Oncology, Biology, Physics, vol. 70, pp. 825-835, 2010.
422. M. Chung, E. M. Balk, M. Brendel, and etal., "Vitamin D and calcium: A systematic review of health outcomes, " Evidence Report/Technology Assessment, vol. 183, pp. 1-420, 2009.
423. P. M. Brannon, E. A. Yetley, R. L. Bailey, and M. F. Picciano, "Overview of conference "Vitamin D and health in the 21st century: An update", "TheAmerican Journal of ClinicalNutrition, vol. 88, pp. 483S-490S, 2008.
424. G. Picotto, A. C. Liaudat, L. Bohl, and N. Tolosa de Talamoni, "Molecular aspects of vitamin d anticancer activity, " Cancer Investigation, vol. 30, no. 8, pp. 604-614, 2012.
425. S. Imtiaz and N. Siddiqui, "Vitamin-D status at breast cancer diagnosis: correlation with social and environmental factors and dietary intake, " Journal of Ayub Medical College, Abbottabad, vol. 26, no. 2, pp. 186-190, 2014.
426. Z. Hong, C. Tian, and X. Zhang, "Dietary calcium intake, vitamin D levels, and breast cancer risk: A dose-response analysis of observational studies, " Breast Cancer Research and Treatment, vol. 136, no. 1, pp. 309-312, 2012.
427. A. Hjart?aker, M. Thoresen, D. Engeset, and E. Lund, "Dairy consumption and calcium intake and risk of breast cancer in a prospective cohort: The NorwegianWomen and Cancer study, " Cancer Causes and Control, vol. 21, no. 11, pp. 1875-1885, 2010.
428. L. N. Anderson, "Vitamin D-related genetic variants, interactions with vitamin D exposure, and breast cancer risk among caucasian women in Ontario, " Cancer Epidemiology, Biomarkers & Prevention, vol. 20, no. 8, pp. 1708-1717, 2011.
429. M. L. McCullough, R. M. Bostick, and T. L. Mayo, "Vitamin D gene pathway polymorphisms and risk of colorectal, breast, and prostate cancer, " Annual Review of Nutrition, vol. 29, pp. 111-132, 2009.
430. Y. N. Urata, E. C. D. Lyra, M. L. H. Katayama et al., "Calcitriol supplementation effects on Ki67 expression and transcriptional profile of breast cancer specimens from post-menopausal patients, " Clinical Nutrition, vol. 33, no. 1, pp. 136-142, 2014.
431. S. Singh, J. Cuzick, D. Mesher, B. Richmond, and A. Howell, "Effect of baseline serum vitamin D levels on aromatase inhibitors induced musculoskeletal symptoms: Results from the IBIS-II, chemoprevention study using anastrozole, " Breast Cancer Research and Treatment, vol. 132, no. 2, pp. 625-629, 2012.
432. A. C. Shapiro, S. A. Adlis, K. Robien et al., "Erratum: Randomized, blinded trial of vitamin D3 for treating aromatase inhibitor-associated musculoskeletal symptoms (AIMSS), " Breast Cancer Research and Treatment, vol. 157, no. 2, p. 403, 2016.
433. M. Chung, J. Lee, T. Terasawa, J. Lau, and T. A. Trikalinos, "Vitamin D with or without calcium supplementation for prevention of cancer and fractures: An updated meta-analysis for the U. S. Preventive Services Task Force, " Annals of Internal Medicine, vol. 155, no. 12, pp. 827-838, 2011.
434. S. Bourke, M. J. Bolland, A. Grey et al., "The impact of dietary calcium intake and vitamin D status on the effects of zoledronate, " Osteoporosis International, vol. 24, no. 1, pp. 349-354, 2013.
435. Y. Rhee, K. Song, S. Park, H. S. Park, S.-K. Lim, and B. W. Park, "Efficacy of a combined alendronate and calcitriol agent (Maxmarvil-) in Korean postmenopausal women with early breast cancer receiving aromatase inhibitor: A double-blind, randomized, placebo-controlled study, " Endocrine Journal, vol. 60, no. 2, pp. 167-172, 2013.
436. S. D. Manshadi, L. Ishiguro, K.-J. Sohn et al., "Folic acid supplementation promotes mammary tumor progression in a rat model, " PLoS ONE, vol. 9, no. 1, Article ID e84635, 2014.
437. M. Lajous, J. de Batlle, C. Ricci et al., "Biomarkers of folate and vitamin B12 and breast cancer risk: report from the EPIC cohort, " International Journal ofCancer, vol. 140, no. 6, pp. 1246-1259, 2017.
438. C. M. Ulrich, "Folate and cancer prevention: A closer look at a complex picture, "The American Journal of Clinical Nutrition, vol. 86, pp. 271-273, 2007.
439. P. Bougnoux, N. Hajjaji, K. Maheo, C. Couet, and S. Chevalier, "Fatty acids and breast cancer: sensitization to treatments and prevention of metastatic re-growth, " Progress in Lipid Research, vol. 49, no. 1, pp. 76-86, 2010.